

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification⁶ : C12N 15/10, C12Q 1/68, C07H 21/04</p>	<p>A1</p>	<p>(11) International Publication Number: WO 99/14318 (43) International Publication Date: 25 March 1999 (25.03.99)</p>
<p>(21) International Application Number: PCT/US98/19312 (22) International Filing Date: 16 September 1998 (16.09.98) (30) Priority Data: 60/059,017 16 September 1997 (16.09.97) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 60/059,017 (CIP) Filed on 16 September 1997 (16.09.97) (71) Applicant (for all designated States except US): BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM [US/US]; 201 West Seventh Street, Austin, TX 78701 (US). (72) Inventor; and (75) Inventor/Applicant (for US only): EVANS, Glen, A. [US/US]; 4606 Cedar Springs #2027, Dallas, TX 75219 (US). (74) Agent: McMILLIAN, Nabeela, R.; Arnold, White & Durkee, P.O. Box 4433, Houston, TX 77210 (US).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>

(54) Title: METHOD FOR THE COMPLETE CHEMICAL SYNTHESIS AND ASSEMBLY OF GENES AND GENOMES

(57) Abstract

The present invention relates generally to the fields of oligonucleotide synthesis. More particularly, it concerns the assembly of genes and genomes of completely synthetic artificial organisms. Thus, the present invention outlines a novel approach to utilizing the results of genomic sequence information by computer directed gene synthesis based on computing on the human genome database. Specifically, the present invention contemplates and describes the chemical synthesis and resynthesis of genes defined by the genome sequence in a host vector and transfer and expression of these sequences into suitable hosts.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

DESCRIPTION

METHOD FOR THE COMPLETE CHEMICAL SYNTHESIS AND ASSEMBLY OF GENES AND GENOMES

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates generally to the fields of oligonucleotide synthesis. More particularly, it concerns the assembly of genes and genomes of completely synthetic artificial organisms.

2. Description of Related Art

Present research and commercial applications in molecular biology are based upon recombinant DNA developed in the 1970's. A critical facet of recombinant DNA is molecular cloning in plasmids, covered under seminal patent of Cohen and Boyer (U.S. Patent 4,740,470 "Biologically functional molecular chimeras"). This patent teaches a method for the "cutting and splicing" of DNA molecules based upon restriction endonucleases, the introduction of these "recombinant" molecules into host cells, and their replication in the bacterial hosts. This technique is the basis of all molecular cloning for research and commercial purposes carried out for the past 20 years and the basis of the field of molecular biology and genetics.

Recombinant DNA technology is a powerful technology, but is limited in utility to modifications of existing DNA sequences which are modified through 1) restriction enzyme cleavage sites, 2) PAC primers for amplification, 3) site-specific mutagenesis, and other techniques. The creation of an entirely new molecule, or the substantial modification of existing molecules, is extremely time consuming, expensive, requires complex and multiple steps, and in some cases is impossible. Recombinant DNA technology does not permit the creation of entirely artificial molecules, genes, genomes or organisms, but only modifications of naturally-occurring organisms.

30

Current biotechnology for industrial production, for drug design and development, for potential applications of vaccine development and genetic therapy, and for agricultural and

5 environmental use of recombinant DNA, depends on naturally-occurring organisms and DNA molecules. To create or engineer new or novel functions, or to modify organisms for specialized use (such as producing a human hormone), requires substantially complex, time consuming and difficult manipulations of naturally-occurring DNA molecules. In some cases, changes to naturally-occurring DNA are so complex that they are not possible in practice.

10 Thus, there is a need for technology that allows the creation of novel DNA molecules in a single step without requiring the use of any existing recombinant or naturally-occurring DNA.

SUMMARY OF THE INVENTION

15 The present invention addresses the limitations in present recombinant nucleic acid manipulations by providing a fast, efficient means for generating practically any nucleic acid sequence, including entire genes, chromosomal segments, chromosomes and genomes. Because this approach is based on an completely synthetic approach, there are no limitations, such as the availability of existing nucleic acids, to hinder the construction of even very large

20 segments of nucleic acid.

Thus, in a first embodiment, there is provided a method for the construction of a double-stranded DNA segment comprising the steps of (i) providing two sets of single-stranded oligonucleotides, wherein (a) the first set comprises the entire plus strand of said DNA

25 segment, (b) the second set comprises the entire minus strand of said DNA segment, and (c) each of said first set of oligonucleotides being complementary to two oligonucleotides of said second set of oligonucleotides, (ii) annealing said first and said second set of oligonucleotides, and (iii) treating said annealed oligonucleotides with a ligating enzyme. Optional steps provide for the synthesis of the oligonucleotide sets and the transformation of host cells with the

30 resulting DNA segment.

In particular embodiments, the DNA segment is 100, 200, 300, 400, 800, 100, 1500, 200, 4000, 8000, 10000, 12000, 18,000, 20000, 40,000, 80,000; 10^6 , 10^7 , 10^8 , 10^9 or more base pairs in length. Indeed, it is contemplated that the methods of the present invention will be

35 able to create entire artificial genomes of lengths comparable to known bacterial, yeast, viral, mammalian, amphibian, reptilian, avian genomes. In more particular embodiments, the DNA

5 segment is a gene encoding a protein of interest. The DNA segment further may include non-coding elements such as origins of replication, telomeres, promoters, enhancers, transcription and translation start and stop signals, introns, exon splice sites, chromatin scaffold components and other regulatory sequences. The DNA segment may comprises multiple genes, chromosomal segments, chromosomes and even entire genomes. The DNA segments may be
10 derived from prokaryotic or eukaryotic sequences including bacterial, yeast, viral, mammalian, amphibian, reptilian, avian, plants, archebacteria and other DNA containing living organisms.

The oligonucleotide sets preferably are comprised oligonucleotides of between about 15 and 100 bases and more preferably between about 20 and 50 bases. Specific lengths include,
15 but are not limited to 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 and 100. Depending on the size, the overlap between the oligonucleotides of the two sets may be designed to be between 5 and 75
20 bases per oligonucleotide pair.

The oligonucleotides preferably are treated with polynucleotide kinase, for example, T4 polynucleotide kinase. The kinasing can be performed prior to mixing of the oligonucleotides set or after, but before annealing. After annealing, the oligonucleotides are treated with an
25 enzyme having a ligating function. For example, a DNA ligase typically will be employed for this function. However, topoisomerase, which does not require 5' phosphorylation, is rapid and operates at room temperature, and may be used instead of ligase.

In a second embodiment, there is provided a method for construction of a double-
30 stranded DNA segment comprising the steps of (i) providing two sets of single-stranded oligonucleotides, wherein (a) the first set comprises the entire plus strand of said DNA segment, (b) the second set comprises the entire minus strand of said DNA segment, and (c) each of said first set of oligonucleotides being complementary to two oligonucleotides of said second set of oligonucleotides, (ii) annealing pairs of complementary oligonucleotides to
35 produce a set of first annealed products, wherein each pair comprises an oligonucleotide from each of said first and said second sets of oligonucleotides, (iii) annealing pairs of first annealed

- 5 products having complementary sequences to produce a set of second annealed products, (iv) repeating the process until all annealed products have been annealed into a single DNA segment, and (v) treating said annealed products with ligating enzyme.

In a third embodiment, there is provided a method for the construction of a double-
10 stranded DNA segment comprising the steps of (i) providing two sets of single-stranded oligonucleotides, wherein (a) the first set comprises the entire plus strand of said DNA segment, (b) the second set comprises the entire minus strand of said DNA segment, and (c) each of said first set of oligonucleotides being complementary to two oligonucleotides of said second set of oligonucleotides, (ii) annealing said the 5' terminal oligonucleotide of said first
15 set of oligonucleotide with the 3' terminal oligonucleotide of said second set of oligonucleotides, (iii) annealing the next most 5' terminal oligonucleotide of said first set of oligonucleotides with the product of step (ii), (iv) annealing the next most 3' terminal oligonucleotide of said second set of oligonucleotides with the product of step (iii), (v) repeating the process until all oligonucleotides of said first and said second sets have been
20 annealed, and (vi) treating said annealed oligonucleotides with ligating enzyme. Optional steps provide for the synthesis of the oligonucleotide sets and the transformation of host cells with the resulting DNA segment. In a preferred embodiment, the 5' terminal oligonucleotide of the first set is attached to a support, which process may include the additional step of removing the DNA segment from the support. The support may be any support known in the art, for
25 example, a microtiter plate, a filter, polystyrene beads, polystyrene tray, magnetic beads, agarose and the like.

Annealing conditions may be adjusted based on the particular strategy used for annealing, the size and composition of the oligonucleotides, and the extent of overlap between
30 the oligonucleotides of the first and second sets. For example, where all the oligonucleotides are mixed together prior to annealing, heating the mixture to 80°C, followed by slow annealing for between 1 to 12 h is conducted. Thus, annealing may be conducted for about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, or about 10 h. However, in other embodiments, the annealing time may be as long as 24 h.

5 With the aid of a computer, the inventor is able to direct synthesis of a vector/gene combination using a high throughput oligonucleotide synthesizer as a set of overlapping component oligonucleotides. The oligonucleotides are assembled using a robotic combinatoric assembly strategy and the assembly ligated using DNA ligase or topoisomerase, followed by transformation into a suitable host strain. In a particular embodiment, this invention generates a
10 set of bacterial strains containing a viable expression vector for all genes in a defined region of the genome. In other embodiments, a yeast or baculovirus expression vector system is also contemplated to allow expression of each gene in a chromosomal region in a eukaryotic host. In yet another embodiment, it the present invention allows one of skill in the art to devise a "designer gene" strategy wherein a gene or genomes or virtually any structure may be readily
15 designed, synthesized and expressed. Thus, eventually the technology described herein may be employed to create entire genomes for introduction into host cells for the creation of entirely artificial designer living organisms.

In specific embodiments, the present invention provides a method for the synthesis of a
20 replication-competent, double-stranded polynucleotide, wherein the polynucleotide comprises an origin of replication, a first coding region and a first regulatory element directing the expression of the first coding region.

Additionally the method may further comprise the step of amplifying the double-
25 stranded polynucleotide. In specific embodiments, the double-stranded polynucleotide comprises 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 5000, 10×10^3 , 20×10^3 , 30×10^3 , 40×10^3 , 50×10^3 , 60×10^3 , 70×10^3 , 80×10^3 , 90×10^3 , 1×10^4 , 1×10^5 , 1×10^6 , 1×10^7 , 1×10^8 , 1×10^9 or 1×10^{10} base pairs in length. The first regulatory element may be a promoter. In certain embodiments, the double-stranded polynucleotide further comprises a
30 second regulatory element, the second regulatory element being a polyadenylation signal. In yet further embodiments, the double-stranded polynucleotide comprises a plurality of coding regions and a plurality of regulatory elements. Specifically, it is contemplated that the coding regions encode products that comprise a biochemical pathway. In particular embodiments the biochemical pathway is glycolysis. More particularly, it is contemplated that the coding
35 regions encode enzymes selected from the group consisting of hexokinase, phosphohexose isomerase, phosphofructokinase-1, aldolase, triose-phosphate isomerase, glyceraldehyde-3-

5 phosphate dehydrogenase, phosphoglycerate kinase, phosphoglycerate mutase, enolase and pyruvate kinase enzymes of the glycolytic pathway.

In other embodiments, the biochemical pathway is lipid synthesis, cofactor synthesis. Particularly contemplated are synthesis of lipoic acid, riboflavin synthesis nucleotide synthesis.
10 the nucleotide may be a purine or a pyrimidine.

In certain other embodiments it is contemplated that the coding regions encode enzymes involved in a cellular process selected from the group consisting of cell division, chaperone, detoxification, peptide secretion, energy metabolism, regulatory function, DNA replication,
15 transcription, RNA processing and tRNA modification. In preferred embodiments, the energy metabolism is oxidative phosphorylation.

It is contemplated that the double-stranded polynucleotide is a DNA or an RNA. In preferred embodiments, the double-stranded polynucleotide may be a chromosome. The
20 double-stranded polynucleotide may be an expression construct. Specifically, the expression construct may be a bacterial expression construct, a mammalian expression construct or a viral expression construct. In particular embodiments, the double-stranded polynucleotide comprises a genome selected from the group consisting of bacterial genome, yeast genome, viral genome, mammalian genome, amphibian genome and avian genome.

25 In those embodiments in which the genome is a viral genome, the viral genome may be selected from the group consisting of retrovirus, adenovirus, vaccinia virus, herpesvirus and adeno-associated virus.

30 The present invention further provides a method of producing a viral particle.

Another embodiment provides a method of producing an artificial genome, wherein the chromosome comprises all coding regions and regulatory elements found in a corresponding natural chromosome. In specific embodiments, the corresponding natural chromosome is a
35 human mitochondrial genome. In other embodiments, the corresponding natural chromosome is a chloroplast genome.

5

Also provided is a method of producing an artificial genetic system, wherein the system comprises all coding regions and regulatory elements found in a corresponding natural biochemical pathway. Such a biochemical pathway will likely possess a group of enzymes that serially metabolize a compound. In particularly preferred embodiments, the biochemical pathway comprises the activities required for glycolysis. In other embodiments, the biochemical pathway comprises the enzymes required for electron transport. In still further embodiments, the biochemical pathway comprises the enzyme activities required for photosynthesis.

15 Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

BRIEF DESCRIPTION OF THE DRAWINGS

The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.

FIG. 1. Flow diagram of the Jurassic Park paradigm for the construction of synthetic organisms and reassembly of living organisms.

FIG. 2. Flow diagram of the strategy of synthetic genetics and assembly of organisms.

FIG. 3. Flow diagram of the eight-step strategy for combinatoric assembly of oligonucleotides into complete genes or genomes.

5

FIG. 4A-FIG. 4C. Design of plasmid synlux4. The sequence of 4800 is annotated with the locations of lux A+B genes, neomycin/kanamycin phosphotransferase and pUC19 sequences.

10

FIG. 5A-FIG. 5F. List of component oligonucleotides derived from the sequence of Synlux4 in Figure 4A-FIG. 4C.

FIG. 6A-FIG. 6B. Schema for the combinatoric assembly of synthetic plasmids from component oligonucleotides.

15

FIG. 7A-FIG. 7G. SynGene program for generating overlapping oligonucleotides sufficient to reassemble the gene or plasmid.

DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

The complete sequence of complex genomes, including the human genome, make large scale functional approaches to genetics possible. The present invention outlines a novel approach to utilizing the results of genomic sequence information by computer directed gene synthesis based on computing on the human genome database. Specifically, the invention describes chemical synthesis and resynthesis of genes for transfer of these genes into a suitable host cells.

The present invention provides methods that can be used to synthesize *de novo*, DNA segments that encode sets of genes, either naturally occurring genes expressed from natural or artificial promoter constructs or artificial genes derived from synthetic DNA sequences, which encodes elements of biological systems that perform a specified function or attribution of an artificial organism as well as entire genomes. In producing such systems and genomes, the present invention provides the synthesis of a replication-competent, double-stranded polynucleotide, wherein the polynucleotide has an origin of replication, a first coding region and a first regulatory element directing the expression of the first coding region. By replication competent, it is meant that the polynucleotide is capable of directing its own replication. Thus, it is envisioned that the polynucleotide will possess all the *cis*-acting signals required to facilitate its own synthesis. In this respect, the polynucleotide will be similar to a plasmid or a

5 virus, such that once placed within a cell, it is able to be replicated by a combination of the polynucleotide's and cellular functions.

Thus, using the techniques of the present invention, one of skill in the art can create an artificial genome that is capable of encoding all the activities required for sustaining its own
10 existence. Also contemplated are artificial genetic systems that are capable of encoding enzymes and activities of a particular biochemical pathway. In such a system, it will be desirable to have all the activities present such that the whole biochemical pathway will operate. The co-expression of a set of enzymes required for a particular pathway constitutes a complete genetic or biological system. For example, the co-expression of the enzymes
15 involved in glycolysis constitutes a complete genetic system for the production of energy in the form of ATP from glucose. Such systems for energy production may include groups of enzymes which naturally or artificially serially metabolize a set of compounds.

The types of biochemical pathways would include but are not limited to those for the
20 biosynthesis of cofactors prosthetic groups and carriers (lipoate synthesis, riboflavin synthesis pyridine nucleotide synthesis); the biosynthesis of the cell envelopes (membranes, lipoproteins, porins, surface polysaccharides, lipopolysaccharides, antigens and surface structures); cellular processes including cell division, chaperones, detoxification, protein secretion, central intermediary metabolism (energy production via phosphorus compounds and other); energy
25 metabolism including aerobic, anaerobic, ATP proton motive force interconversions, electron transport, glycolysis triose phosphate pathway, pyruvate dehydrogenase, sugar metabolism; purine, pyrimidine nucleotide synthesis, including 2'deoxyribonucleotide synthesis, nucleotide and nucleoside interconversion, salvage of nucleoside and nucleotides, sugar-nucleotide biosynthesis and conversion; regulatory functions including transcriptional and translational
30 controls, DNA replication including degradation of DNA, DNA replication, restriction modification, recombination and repair; transcription including degradation of DNA, DNA-dependent RNA polymerase and transcription factors; RNA processing; translation including amino acyl tRNA synthetases, degradation of peptides and glycopeptides, protein modification, ribosome synthesis and modification, tRNA modification; translation factors transport and
35 binding proteins including amino acid, peptide, amine carbohydrate, organic alcohol, organic

- 5 acid and cation transport; and other systems for the adaptation, specific function or survival of an artificial organism.

A. Definitions

DNA segment - a linear piece of DNA having a double-stranded region and both 5'-
10 and 3'-ends; the segment may be of any length sufficiently long to be created by the hybridization of at least two oligonucleotides having complementary regions.

Oligonucleotides - small DNA segments, single-stranded or double-stranded, comprised of the nucleotide bases A, T, G and C linked through phosphate bonds;
15 oligonucleotides typically range from about 10 to 100 base pairs.

Plus strand - by convention, the single-strand of a double-stranded DNA that starts with the 5' end to the left as one reads the sequence.

20 **Minus strand** - by convention, the single-strand of a double-stranded DNA that starts with the 3' end to the left as one reads the sequence.

Complementary - where two nucleic acids have at least a portion of their sequences, when read in opposite (5'→3'; 3'→5') direction, that pair sequential nucleotides in the
25 following fashion: A-T, G-C, T-A, G-C.

Oligonucleotide sets - a plurality of oligonucleotides that, taken together, comprise the sequence of a plus or minus strand of a DNA segment.

30 **Annealed products** - two or more oligonucleotides having complementary regions, where they are permitted, under proper conditions, to base pair, thereby producing double stranded regions.

5 **B. The Present Invention**

The present invention describes methods for enabling the creation of DNA molecules, genomes and entire artificial living organisms based upon information only, without the requirement for existing genes, DNA molecules or genomes.

10 The methods of the present invention are diagrammed in FIG. 1 and FIG. 2 and generally involve the following steps. Generally, using simple computer software, comprising sets of gene parts and functional elements it is possible to construct a virtual polynucleotide in the computer. This polynucleotide consists of a string of DNA bases, G, A, T or C, comprising for example an entire artificial genome in a linear string. For transfer of the synthetic gene into
15 for example, bacterial cells the polynucleotide should contain the sequence for a bacterial (such as pBR322) origin of replication. For transfer into eukaryotic cells, it should contain the origin of replication of a mammalian virus, chromosome or subcellular component such as mitochondria.

20 Following construction, simple computer software is then used to break down the genome sequence into a set of overlapping oligonucleotides of specified length. This results in a set of shorter DNA sequences which overlap to cover the entire genome in overlapping sets. Typically, a gene of 1000 bases pairs would be broken down into 20 100-mers where 10 of these comprise one strand and 10 of these comprise the other strand. They would be selected to
25 overlap on each strand by 25 to 50 base pairs.

This step is followed by direction of chemical synthesis of each of the overlapping set of oligonucleotides using an array type synthesizer and phosphoramidite chemistry resulting in an array of synthesized oligomers. The next step is to balance concentration of each oligomer and
30 pool the oligomers so that a single mixture contains equal concentrations of each. The mixed oligonucleotides are treated with T4 polynucleotide kinase to 5' phosphorylate the oligonucleotides. The next step is to carry out a "slow" annealing step to co-anneal all of the oligomers into the sequence of the predicted gene or genome. This is done by heating the mixture to 80°C, then allowing it to cool slowly to room temperature over several hours. The
35 mixture of oligonucleotides is then treated with T4 DNA ligase (or alternatively topoisomerase)

5 to join the oligonucleotides. The oligonucleotides are then transferred into competent host cells.

The above technique represents a "combinatorial" assembly strategy where all oligonucleotides are jointly co-annealed by temperature-based slow annealing. A variation on
10 this strategy, which may be more suitable for very long genes or genomes, such as greater than 5,000 base pairs final length, is as follows. Using simple computer software, comprising sets of gene parts and functional elements, a virtual gene or genome is constructed in the computer. This gene or genome would consist of a string of DNA bases, G, A, T or C, comprising the entire genome in a linear string. For transfer of the synthetic gene into bacterial cells, it should
15 contain the sequence for a bacterial (such as pBR322) origin of replication.

The next step is to carry out a ligation chain reaction using a new oligonucleotide addition each step. With this procedure, the first oligonucleotide in the chain is attached to a solid support (such as an agarose bead). The second is added along with DNA ligase, and
20 annealing and ligation reaction carried out, and the beads are washed. The second, overlapping oligonucleotide from the opposite strand is added, annealed and ligation carried out. The third oligonucleotide is added and ligation carried out. This procedure is replicated until all oligonucleotides are added and ligated. This procedure is best carried out for long sequences using an automated device. The DNA sequence is removed from the solid support, a final
25 ligation (is circular) is carried out, and the molecule transferred into host cells.

Alternatively, it is contemplated that if the ligation kinetics allow all the oligonucleotides may be placed in a mixture and ligation be allowed to proceed. In yet another embodiment, a series of smaller polynucleotides may be made by ligating 2, 3, 4, 5, 6, or 7
30 oligonucleotides into one sequence and adding this to another sequence comprising a similar number of oligonucleotides parts.

The ligase chain reaction ("LCR"), disclosed in EPO No. 320 308, is incorporated herein by reference in its entirety. In LCR, two complementary probe pairs are prepared, and in
35 the presence of the target sequence, each pair will bind to opposite complementary strands of the target such that they abut. In the presence of a ligase, the two probe pairs will link to form a

5 single unit. By temperature cycling, as in PCR™, bound ligated units dissociate from the target and then serve as "target sequences" for ligation of excess probe pairs. U.S. Patent 4,883,750 describes a method similar to LCR for binding probe pairs to a target sequence. The following sections describe these methods in further detail.

10 C. Nucleic Acids

The present invention discloses the artificial synthesis of genes. In one embodiment of the present invention, the artificial genes can be transferred into cells to confer a particular function either as discrete units or as part of artificial chromosomes or genome. One will generally prefer to design oligonucleotides having stretches of 15 to 100 nucleotides, 25 to 200 nucleotides or even
15 longer where desired. Such fragments may be readily prepared by, directly synthesizing the fragment by chemical means as described below.

Accordingly, the nucleotide sequences of the invention may be used for their ability to selectively form duplex molecules with complementary stretches of genes or RNAs or to provide
20 primers for amplification of DNA or RNA from tissues. Depending on the application envisioned, one will desire to employ varying conditions of hybridization to achieve varying degrees of hybridization selectivity. Typically high selectivity is favored.

For applications requiring high selectivity, one typically will desire to employ relatively
25 stringent conditions to form the hybrids, *e.g.*, one will select relatively low salt and/or high temperature conditions, such as provided by about 0.02 M to about 0.10 M NaCl at temperatures of about 50°C to about 70°C. Such high stringency conditions tolerate little, if any, mismatch between the oligonucleotide and the template or target strand. It generally is appreciated that conditions can be rendered more stringent by the addition of increasing amounts of formamide.

30

For certain applications, for example, by analogy to, substitution of nucleotides by site-directed mutagenesis, it is appreciated that lower stringency conditions may be used. Under these conditions, hybridization may occur even though the sequences of probe and target strand are not perfectly complementary, but are mismatched at one or more positions. Conditions may be
35 rendered less stringent by increasing salt concentration and decreasing temperature. For example, a medium stringency condition could be provided by about 0.1 to 0.25 M NaCl at temperatures of

5 about 37°C to about 55°C, while a low stringency condition could be provided by about 0.15 M to about 0.9 M salt, at temperatures ranging from about 20°C to about 55°C. Thus, hybridization conditions can be readily manipulated depending on the desired results.

10 In certain embodiments, it will be advantageous to determining the hybridization of oligonucleotides by employing as a label. A wide variety of appropriate indicator means are known in the art, including fluorescent, radioactive, enzymatic or other ligands, such as avidin/biotin, which are capable of being detected. In preferred embodiments, one may desire to employ a fluorescent label or an enzyme tag such as urease, alkaline phosphatase or peroxidase, instead of radioactive or other environmentally undesirable reagents. In the case of enzyme tags,
15 colorimetric indicator substrates are known that can be employed to provide a detection means visible to the human eye or spectrophotometrically, to identify whether specific hybridization with complementary oligonucleotide has occurred.

In embodiments involving a solid phase, for example the first oligonucleotide is adsorbed
20 or otherwise affixed to a selected matrix or surface. This fixed, single-stranded nucleic acid is then subjected to hybridization with the complementary oligonucleotides under desired conditions. The selected conditions will also depend on the particular circumstances based on the particular criteria required (depending, for example, on the G+C content, type of target nucleic acid, source of nucleic acid, size of hybridization probe, *etc.*). Following washing of the
25 hybridized surface to remove non-specifically bound oligonucleotides, the hybridization may be detected, or even quantified, by means of the label.

For applications in which the nucleic acid segments of the present invention are incorporated into vectors, such as plasmids, cosmids or viruses, these segments may be combined
30 with other DNA sequences, such as promoters, polyadenylation signals, restriction enzyme sites, multiple cloning sites, other coding segments, and the like, such that their overall length may vary considerably. It is contemplated that a nucleic acid fragment of almost any length may be employed, with the total length preferably being limited by the ease of preparation and use in the intended recombinant DNA protocol.

35

5 DNA segments encoding a specific gene may be introduced into recombinant host cells and employed for expressing a specific structural or regulatory protein. Alternatively, through the application of genetic engineering techniques, subportions or derivatives of selected genes may be employed. Upstream regions containing regulatory regions such as promoter regions may be isolated and subsequently employed for expression of the selected gene.

10

The nucleic acids employed may encode antisense constructs that hybridize, under intracellular conditions, to a nucleic acid of interest. The term "antisense construct" is intended to refer to nucleic acids, preferably oligonucleotides, that are complementary to the base sequences of a target DNA. Antisense oligonucleotides, when introduced into a target cell,
15 specifically bind to their target nucleic acid and interfere with transcription, RNA processing, transport, translation and/or stability. Antisense constructs may be designed to bind to the promoter and other control regions, exons, introns or even exon-intron boundaries of a gene.

Other sequences with lower degrees of homology also are contemplated. For example,
20 an antisense construct which has limited regions of high homology, but also contains a non-homologous region (e.g., a ribozyme) could be designed. These molecules, though having less than 50% homology, would bind to target sequences under appropriate conditions.

In certain embodiments, one may wish to employ antisense constructs which include
25 other elements, for example, those which include C-5 propyne pyrimidines. Oligonucleotides which contain C-5 propyne analogues of uridine and cytidine have been shown to bind RNA with high affinity and to be potent antisense inhibitors of gene expression (Wagner *et al.*, 1993).

30 According to the present invention, DNA segments of a variety of sizes will be produced. These DNA segments will, by definition, be linear molecules. As such, they typically will be modified before further use. These modifications include, in one embodiment, the restriction of the segments to produce one or more "sticky ends" compatible with complementary ends of other molecules, including those in vectors capable of supporting the
35 replication of the DNA segment. This manipulation facilitates "cloning" of the segments.

5 Typically, cloning involves the use of restriction endonucleases, which cleave at particular sites within DNA strands, to prepare a DNA segment for transfer into a cloning vehicle. Ligation of the compatible ends (which include blunt ends) using a DNA ligase completes the reaction. Depending on the situation, the cloning vehicle may comprises a relatively small portion of DNA, compared to the insert. Alternatively, the cloning vehicle may
10 be extremely complex and include a variety of features that will affect the replication and function of the DNA segment. In certain embodiments, a rare cutter site may be introduced into the end of the polynucleotide sequence.

 Cloning vehicles include plasmids such as the pUC series, Bluescript™ vectors and a
15 variety of other vehicles with multipurpose cloning sites, selectable markers and origins of replication. Because of the nature of the present invention, the cloning vehicles may include such complex molecules as phagemids and cosmids, which hold relatively large pieces of DNA. In addition, the generation of artificial chromosomes, and even genomes.

20 Following cloning into a suitable vector, the construct then is transferred into a compatible host cell. A variety of different gene transfer techniques are described elsewhere in this document. Culture of the host cells for the intended purpose (amplification, expression, subcloning) follows.

25 Throughout this application, the term "expression construct" is meant to include a particular kind of cloning vehicle containing a nucleic acid coding for a gene product in which part or all of the nucleic acid encoding sequence is capable of being transcribed. The transcript may be translated into a protein, but it need not be. Thus, in certain embodiments, expression includes both transcription of a gene and translation of a RNA into a gene product. In other
30 embodiments, expression only includes transcription of the nucleic acid, for example, to generate antisense constructs.

 In preferred embodiments, the nucleic acid is under transcriptional control of a promoter. A "promoter" refers to a DNA sequence recognized by the synthetic machinery of
35 the cell, or introduced synthetic machinery, required to initiate the specific transcription of a gene. The phrase "under transcriptional control" means that the promoter is in the correct

- 5 location and orientation in relation to the nucleic acid to control RNA polymerase initiation and expression of the gene.

The term promoter will be used here to refer to a group of transcriptional control modules that are clustered around the initiation site for RNA polymerase II. Much of the
10 thinking about how promoters are organized derives from analyses of several viral promoters, including those for the HSV thymidine kinase (tk) and SV40 early transcription units. These studies, augmented by more recent work, have shown that promoters are composed of discrete functional modules, each consisting of approximately 7-20 bp of DNA, and containing one or more recognition sites for transcriptional activator or repressor proteins.

15

At least one module in each promoter functions to position the start site for RNA synthesis. The best known example of this is the TATA box, but in some promoters lacking a TATA box, such as the promoter for the mammalian terminal deoxynucleotidyl transferase gene and the promoter for the SV40 late genes, a discrete element overlying the start site itself
20 helps to fix the place of initiation.

Additional promoter elements regulate the frequency of transcriptional initiation. Typically, these are located in the region 30-110 bp upstream of the start site, although a number of promoters have recently been shown to contain functional elements downstream of
25 the start site as well. The spacing between promoter elements frequently is flexible, so that promoter function is preserved when elements are inverted or moved relative to one another. In the tk promoter, the spacing between promoter elements can be increased to 50 bp apart before activity begins to decline. Depending on the promoter, it appears that individual elements can function either co-operatively or independently to activate transcription.

30

The particular promoter that is employed to control the expression of a nucleic acid is not believed to be critical, so long as it is capable of expressing the nucleic acid in the targeted cell. Thus, where a human cell is targeted, it is preferable to position the nucleic acid coding region adjacent to and under the control of a promoter that is capable of being expressed in a
35 human cell. Generally speaking, such a promoter might include either a human or viral

5 promoter. Preferred promoters include those derived from HSV. Another preferred embodiment is the tetracycline controlled promoter.

In various other embodiments, the human cytomegalovirus (CMV) immediate early gene promoter, the SV40 early promoter and the Rous sarcoma virus long terminal repeat can
10 be used to obtain high-level expression of transgenes. The use of other viral or mammalian cellular or bacterial phage promoters which are well-known in the art to achieve expression of a transgene is contemplated as well, provided that the levels of expression are sufficient for a given purpose. It is envisioned that any elements/promoters may be employed in the context of the present invention. Below is a list of viral promoters, cellular promoters/enhancers and
15 inducible promoters/enhancers that could be used in combination with the nucleic acid encoding a gene of interest in an expression construct. Enhancer/promoter elements contemplated for use with the present invention include but are not limited to Immunoglobulin Heavy Chain, Immunoglobulin Light, Chain T-Cell Receptor, HLA DQ α and DQ β , β -Interferon, Interleukin-2, Interleukin-2 Receptor, MHC Class II 5, MHC Class II HLA-DR α , β -Actin, Muscle Creatine Kinase, Prealbumin (Transferrin), Elastase I, Metallothionein, Collagenase, Albumin Gene, α -Fetoprotein, τ -Globin, β -Globin, e-fos, c-HA-ras, Insulin, Neural Cell Adhesion Molecule (NCAM), α 1-Antitrypsin, H2B (TH2B) Histone, Mouse or Type I
20 Collagen, Glucose-Regulated Proteins (GRP94 and GRP78), Rat Growth Hormone, Human Serum Amyloid A (SAA), Troponin I (TN I), Platelet-Derived Growth Factor, Duchenne
25 Muscular Dystrophy, SV40, Polyoma, Retroviruses, Papilloma Virus, Hepatitis B Virus, Human Immunodeficiency Virus, Cytomegalovirus, Gibbon Ape Leukemia Virus. Inducible promoter elements and their associated inducers are listed in Table 2 below. This list is not intended to be exhaustive of all the possible elements involved in the promotion of transgene expression but, merely, to be exemplary thereof. Additionally, any promoter/enhancer combination (as per the
30 Eukaryotic Promoter Data Base EPDB) could also be used to drive expression of the gene. Eukaryotic cells can support cytoplasmic transcription from certain bacterial promoters if the appropriate bacterial polymerase is provided, either as part of the delivery complex or as an additional genetic expression construct.

35 Enhancers were originally detected as genetic elements that increased transcription from a promoter located at a distant position on the same molecule of DNA. This ability to act over

5 a large distance had little precedent in classic studies of prokaryotic transcriptional regulation. Subsequent work showed that regions of DNA with enhancer activity are organized much like promoters. That is, they are composed of many individual elements, each of which binds to one or more transcriptional proteins.

10 The basic distinction between enhancers and promoters is operational. An enhancer region as a whole must be able to stimulate transcription at a distance; this need not be true of a promoter region or its component elements. On the other hand, a promoter must have one or more elements that direct initiation of RNA synthesis at a particular site and in a particular orientation, whereas enhancers lack these specificities. Promoters and enhancers are often
15 overlapping and contiguous, often seeming to have a very similar modular organization.

5

Table 2

Element	Inducer
MT II	Phorbol Ester (TPA) Heavy metals
MMTV (mouse mammary tumor virus)	Glucocorticoids
β -Interferon	poly(rI)X poly(rc)
Adenovirus 5 E2	Ela
c-jun	Phorbol Ester (TPA), H ₂ O ₂
Collagenase	Phorbol Ester (TPA)
Stromelysin	Phorbol Ester (TPA), IL-1
SV40	Phorbol Ester (TPA)
Murine MX Gene	Interferon, Newcastle Disease Virus
GRP78 Gene	A23187
α -2-Macroglobulin	IL-6
Vimentin	Serum

Table 2 - Continued

Element	Inducer
MHC Class I Gene H-2kB	Interferon
HSP70	Ela, SV40 Large T Antigen
Proliferin	Phorbol Ester-TPA
Tumor Necrosis Factor	FMA
Thyroid Stimulating Hormone α Gene	Thyroid Hormone

10 Use of the baculovirus system will involve high level expression from the powerful polyhedron promoter.

One will typically include a polyadenylation signal to effect proper polyadenylation of the transcript. The nature of the polyadenylation signal is not believed to be crucial to the
 15 successful practice of the invention, and any such sequence may be employed. Preferred

5 embodiments include the SV40 polyadenylation signal and the bovine growth hormone polyadenylation signal, convenient and known to function well in various target cells. Also contemplated as an element of the expression cassette is a terminator. These elements can serve to enhance message levels and to minimize read through from the cassette into other sequences.

10 A specific initiation signal also may be required for efficient translation of coding sequences. These signals include the ATG initiation codon and adjacent sequences. Exogenous translational control signals, including the ATG initiation codon, may need to be provided. One of ordinary skill in the art would readily be capable of determining this and providing the necessary signals. It is well known that the initiation codon must be "in-frame"
15 with the reading frame of the desired coding sequence to ensure translation of the entire insert. The exogenous translational control signals and initiation codons can be either natural or synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements (Bittner *et al.*, 1987).

20 In certain embodiments, it may be desirable to include specialized regions known as telomeres at the end of a genome sequence. Telomeres are repeated sequences found at chromosome ends and it has long been known that chromosomes with truncated ends are unstable, tend to fuse with other chromosomes and are otherwise lost during cell division. Some data suggest that telomeres interaction the nucleoprotein complex and the nuclear matrix.
25 One putative role for telomeres includes stabilizing chromosomes and shielding the ends from degradative enzyme.

 Another possible role for telomeres is in replication. According to present doctrine, replication of DNA requires starts from short RNA primers annealed to the 3'-end of the
30 template. The result of this mechanism is an "end replication problem" in which the region corresponding to the RNA primer is not replicated. Over many cell divisions, this will result in the progressive truncation of the chromosome. It is thought that telomeres may provide a buffer against this effect, at least until they are themselves eliminated by this effect. A further structure to be included in DNA segments is a centromere.

35

5 In certain embodiments of the invention, the delivery of a nucleic acid in a cell may be identified *in vitro* or *in vivo* by including a marker in the expression construct. The marker would result in an identifiable change to the transfected cell permitting easy identification of expression.

10 A number of selection systems may be used, including, but not limited, to the herpes simplex virus thymidine kinase (Wigler *et al.*, 1977), hypoxanthine-guanine phosphoribosyltransferase (Szybalska *et al.*, 1962) and adenine phosphoribosyltransferase genes (Lowy *et al.*, 1980), in *tk*, *hgpri* or *apri* cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for *dhfr*, which confers resistance to
15 methotrexate (Wigler *et al.*, 1980; O'Hare *et al.*, 1981); *gpt*, which confers resistance to mycophenolic acid (Mulligan *et al.*, 1981); *neo*, which confers resistance to the aminoglycoside G-418 (Colberre-Garapin *et al.*, 1981); and *hygro*, which confers resistance to hygromycin.

Usually the inclusion of a drug selection marker aids in cloning and in the selection of
20 transformants, for example, neomycin, puromycin, hygromycin, DHFR, GPT, zeocin and histidinol. Alternatively, enzymes such as herpes simplex virus thymidine kinase (*tk*) (eukaryotic) or chloramphenicol acetyltransferase (CAT) (prokaryotic) may be employed. Immunologic markers also can be employed. The selectable marker employed is not believed to be important, so long as it is capable of being expressed simultaneously with the nucleic acid
25 encoding a gene product. Further examples of selectable markers are well known to one of skill in the art.

In certain embodiments of the invention, the use of internal ribosome binding sites (IRES) elements are used to create multigene, or polycistronic, messages. IRES elements are
30 able to bypass the ribosome scanning model of 5' methylated Cap dependent translation and begin translation at internal sites (Pelletier and Sonenberg, 1988). IRES elements from two members of the picornavirus family (polio and encephalomyocarditis) have been described (Pelletier and Sonenberg, 1988), as well an IRES from a mammalian message (Macejak and Sarnow, 1991). IRES elements can be linked to heterologous open reading frames. Multiple
35 open reading frames can be transcribed together, each separated by an IRES, creating polycistronic messages. By virtue of the IRES element, each open reading frame is accessible

- 5 to ribosomes for efficient translation. Multiple genes can be efficiently expressed using a single promoter/enhancer to transcribe a single message.

Any heterologous open reading frame can be linked to IRES elements. This includes genes for secreted proteins, multi-subunit proteins, encoded by independent genes, intracellular
10 or membrane-bound proteins and selectable markers. In this way, expression of several proteins can be simultaneously engineered into a cell with a single construct and a single selectable marker.

D. Encoded Proteins

- 15 In this application, the inventors use genetic information for creative or synthetic purposes. The complete genome sequence will give a catalog of all genes necessary for the survival, reproduction, evolution and speciation of an organisms and, given suitable high tech tools, the genomic information may be modified or even created from "scratch" in order to synthesize life. Thus it is contemplated that a combination of suitable energy generation genes,
20 regulatory genes, and other functional genes could be constructed which would be sufficient to render an artificial organism with the basic functionalities to enable independent survival.

To meet this goal, the present invention utilizes known cDNA sequences for any given gene to express proteins in an artificial organism. Any protein so expressed in this invention may
25 be modified for particular purposes according to methods well known to those of skill in the art. For example, particular peptide residues may be derivatized or chemically modified in order to alter the immune response or to permit coupling of the peptide to other agents. It also is possible to change particular amino acids within the peptides without disturbing the overall structure or antigenicity of the peptide. Such changes are therefore termed "conservative" changes and tend to
30 rely on the hydrophilicity or polarity of the residue. The size and/or charge of the side chains also are relevant factors in determining which substitutions are conservative.

Once the entire coding sequence of a gene has been determined, the gene can be inserted into an appropriate expression system. The gene can be expressed in any number of different
35 recombinant DNA expression systems to generate large amounts of the polypeptide product,

5 which can then be purified and used to vaccinate animals to generate antisera with which further studies may be conducted.

Examples of expression systems known to the skilled practitioner in the art include bacteria such as *E. coli*, yeast such as *Saccharomyces cerevisia* and *Pichia pastoris*, baculovirus,
10 and mammalian expression systems such as in COS or CHO cells. In one embodiment, polypeptides are expressed in *E. coli* and in baculovirus expression systems. A complete gene can be expressed or, alternatively, fragments of the gene encoding portions of polypeptide can be produced.

15 In one embodiment, the gene sequence encoding the polypeptide is analyzed to detect putative transmembrane sequences. Such sequences are typically very hydrophobic and are readily detected by the use of standard sequence analysis software, such as MacVector (IBI, New Haven, CT). The presence of transmembrane sequences is often deleterious when a recombinant protein is synthesized in many expression systems, especially *E. coli*, as it leads to the production
20 of insoluble aggregates that are difficult to renature into the native conformation of the protein. Deletion of transmembrane sequences typically does not significantly alter the conformation of the remaining protein structure.

Moreover, transmembrane sequences, being by definition embedded within a membrane,
25 are inaccessible. Therefore, antibodies to these sequences will not prove useful for *in vivo* or *in situ* studies. Deletion of transmembrane-encoding sequences from the genes used for expression can be achieved by standard techniques. For example, fortuitously-placed restriction enzyme sites can be used to excise the desired gene fragment, or PCRTM-type amplification can be used to amplify only the desired part of the gene. The skilled practitioner will realize that such changes
30 must be designed so as not to change the translational reading frame for downstream portions of the protein-encoding sequence.

In one embodiment, computer sequence analysis is used to determine the location of the predicted major antigenic determinant epitopes of the polypeptide. Software capable of carrying
35 out this analysis is readily available commercially, for example MacVector (IBI, New Haven, CT). The software typically uses standard algorithms such as the Kyte/Doolittle or Hopp/Woods

5 methods for locating hydrophilic sequences which are characteristically found on the surface of proteins and are, therefore, likely to act as antigenic determinants.

Once this analysis is made, polypeptides can be prepared that contain at least the essential features of the antigenic determinant and that can be employed in the generation of antisera
10 against the polypeptide. Minigenes or gene fusions encoding these determinants can be constructed and inserted into expression vectors by standard methods, for example, using PCR™ methodology.

The gene or gene fragment encoding a polypeptide can be inserted into an expression
15 vector by standard subcloning techniques. In one embodiment, an *E. coli* expression vector is used that produces the recombinant polypeptide as a fusion protein, allowing rapid affinity purification of the protein. Examples of such fusion protein expression systems are the glutathione *S*-transferase system (Pharmacia, Piscataway, NJ), the maltose binding protein system (NEB, Beverly, MA), the FLAG system (IBI, New Haven, CT), and the 6xHis system (Qiagen,
20 Chatsworth, CA).

Some of these systems produce recombinant polypeptides bearing only a small number of additional amino acids, which are unlikely to affect the antigenic ability of the recombinant polypeptide. For example, both the FLAG system and the 6xHis system add only short
25 sequences, both of that are known to be poorly antigenic and which do not adversely affect folding of the polypeptide to its native conformation. Other fusion systems produce polypeptide where it is desirable to excise the fusion partner from the desired polypeptide. In one embodiment, the fusion partner is linked to the recombinant polypeptide by a peptide sequence containing a specific recognition sequence for a protease. Examples of suitable sequences are
30 those recognized by the Tobacco Etch Virus protease (Life Technologies, Gaithersburg, MD) or Factor Xa (New England Biolabs, Beverly, MA).

Recombinant bacterial cells, for example *E. coli*, are grown in any of a number of suitable media, for example LB, and the expression of the recombinant polypeptide induced by adding
35 IPTG to the media or switching incubation to a higher temperature. After culturing the bacteria for a further period of between 2 and 24 h, the cells are collected by centrifugation and washed to

5 remove residual media. The bacterial cells are then lysed, for example, by disruption in a cell homogenizer and centrifuged to separate the dense inclusion bodies and cell membranes from the soluble cell components. This centrifugation can be performed under conditions whereby the dense inclusion bodies are selectively enriched by incorporation of sugars such as sucrose into the buffer and centrifugation at a selective speed.

10

In another embodiment, the expression system used is one driven by the baculovirus polyhedron promoter. The gene encoding the polypeptide can be manipulated by standard techniques in order to facilitate cloning into the baculovirus vector. One baculovirus vector is the pBlueBac vector (Invitrogen, Sorrento, CA). The vector carrying the gene for the polypeptide is
15 transfected into *Spodoptera frugiperda* (Sf9) cells by standard protocols, and the cells are cultured and processed to produce the recombinant antigen. See Summers *et al.*, A MANUAL OF METHODS FOR BACULOVIRUS VECTORS AND INSECT CELL CULTURE PROCEDURES, Texas Agricultural Experimental Station.

20

In designing a gene that encodes a particular polypeptide, the hydropathic index of amino acids may be considered. Table 3 provides a codon table showing the nucleic acids that encode a particular amino acid. The importance of the hydropathic amino acid index in conferring interactive biologic function on a protein is generally understood in the art (Kyte & Doolittle, 1982). The following is a brief discussion of the the hydropathic amino acid index for use in the
25 present invention.

Table 3

Amino Acids			Codons			
Alanine	Ala	A	GCA	GCC	GCG	GCU
Cysteine	Cys	C	UGC	UGU		
Aspartic acid	Asp	D	GAC	GAU		
Glutamic acid	Glu	E	GAA	GAG		
Phenylalanine	Phe	F	UUC	UUU		
Glycine	Gly	G	GGA	GGC	GGG	GGU
Histidine	His	H	CAC	CAU		
Isoleucine	Ile	I	AUA	AUC	AUU	
Lysine	Lys	K	AAA	AAG		
Leucine	Leu	L	UUA	UUG	CUA	CUC CUG CUU
Methionine	Met	M	AUG			
Asparagine	Asn	N	AAC	AAU		
Proline	Pro	P	CCA	CCC	CCG	CCU
Glutamine	Gln	Q	CAA	CAG		
Arginine	Arg	R	AGA	AGG	CGA	CGC CGG CGU
Serine	Ser	S	AGC	AGU	UCA	UCC UCG UCU
Threonine	Thr	T	ACA	ACC	ACG	ACU
Valine	Val	V	GUA	GUC	GUG	GUU
Tryptophan	Trp	W	UGG			
Tyrosine	Tyr	Y	UAC	UAU		

It is accepted that the relative hydropathic character of the amino acid contributes to the secondary structure of the resultant protein, which in turn defines the interaction of the protein with other molecules, for example, enzymes, substrates, receptors, DNA, antibodies, antigens, and the like.

Each amino acid has been assigned a hydropathic index on the basis of their hydrophobicity and charge characteristics (Kyte & Doolittle, 1982), these are: Isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine/cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine (-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); tyrosine (-1.3); proline (-1.6); histidine (-3.2); glutamate (-3.5); glutamine (-3.5); aspartate (-3.5); asparagine (-3.5); lysine (-3.9); and arginine (-4.5).

It is known in the art that certain amino acids may be substituted by other amino acids having a similar hydropathic index or score and still result in a protein with similar biological activity, *i.e.*, still obtain a biological functionally equivalent protein. In making such changes,

- 5 the substitution of amino acids whose hydrophobic indices are within ± 2 is preferred, those which are within ± 1 are particularly preferred, and those within ± 0.5 are even more particularly preferred.

10 It is also understood in the art that the substitution of like amino acids can be made effectively on the basis of hydrophilicity. U.S. Patent 4,554,101, incorporated herein by reference, states that the greatest local average hydrophilicity of a protein, as governed by the hydrophilicity of its adjacent amino acids, correlates with a biological property of the protein.

15 As detailed in U.S. Patent 4,554,101, the following hydrophilicity values have been assigned to amino acid residues: arginine (+3.0); lysine (+3.0); aspartate ($+3.0 \pm 1$); glutamate ($+3.0 \pm 1$); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); threonine (-0.4); proline (-0.5 ± 1); alanine (-0.5); histidine -0.5; cysteine (-1.0); methionine (-1.3); valine (-1.5); leucine (-1.8); isoleucine (-1.8); tyrosine (-2.3); phenylalanine (-2.5); tryptophan (-3.4).

20 It is understood that an amino acid can be substituted for another having a similar hydrophilicity value and still obtain a biologically equivalent and immunologically equivalent protein. In such changes, the substitution of amino acids whose hydrophilicity values are within ± 2 is preferred, those that are within ± 1 are particularly preferred, and those within ± 0.5 are even more particularly preferred.

25

As outlined above, amino acid substitutions are generally based on the relative similarity of the amino acid side-chain substituents, for example, their hydrophobicity, hydrophilicity, charge, size, and the like. Exemplary substitutions that take various of the foregoing characteristics into consideration are well known to those of skill in the art and include: arginine and lysine; glutamate and aspartate; serine and threonine; glutamine and asparagine; and valine, leucine and isoleucine.

30

E. Expression of and Delivery of Genes

I. Expression

35 Once the designer gene, genome or biological system has been made according the methods described herein, the polynucleotides can be expressed as encoded peptides or proteins

5 of the gene, genome or biological system. The engineering of the polynucleotides for expression in a prokaryotic or eukaryotic system may be performed by techniques generally known to those of skill in recombinant expression. Therefore, promoters and other elements specific to a bacterial mammalian or other system may be included in the polynucleotide sequence. It is believed that virtually any expression system may be employed in the
10 expression of the claimed nucleic acid sequences.

The artificially generated polynucleotide sequences are suitable for eukaryotic expression, as the host cell will generally process the genomic transcripts to yield functional mRNA for translation into protein. It is believed that the use of a designer gene version will
15 provide advantages in that the size of the gene will generally be much smaller and more readily employed to transfect the targeted cell than will a genomic gene, which will typically be up to an order of magnitude larger than the designer gene. However, the inventor does not exclude the possibility of employing a genomic version of a particular gene where desired.

20 As used herein, the terms "engineered" and "recombinant" cells are intended to refer to a cell into which an exogenous polynucleotide described herein has been introduced. Therefore, engineered cells are distinguishable from naturally-occurring cells which do not contain a recombinantly introduced exogenous polynucleotide. Engineered cells are thus cells having a gene or genes introduced through the hand of man. Recombinant cells include those having an
25 introduced polynucleotides, and also include polynucleotides positioned adjacent to a promoter not naturally associated with the particular introduced gene.

To express a recombinant encoded protein or peptide, whether mutant or wild-type, in accordance with the present invention one would prepare an expression vector that comprises
30 one of the claimed isolated nucleic acids under the control of one or more promoters. To bring a coding sequence "under the control of" a promoter, one positions the 5' end of the translational initiation site of the reading frame generally between about 1 and 50 nucleotides "downstream" of (*i.e.*, 3' of) the chosen promoter. The "upstream" promoter stimulates transcription of the inserted DNA and promotes expression of the encoded recombinant protein.
35 This is the meaning of "recombinant expression" in the context used here.

5 Many standard techniques are available to construct expression vectors containing the appropriate nucleic acids and transcriptional/translational control sequences in order to achieve protein or peptide expression in a variety of host-expression systems. Cell types available for expression include, but are not limited to, bacteria, such as *E. coli* and *B. subtilis* transformed with recombinant phage DNA, plasmid DNA or cosmid DNA expression vectors.

10

Certain examples of prokaryotic hosts are *E. coli* strain RR1, *E. coli* LE392, *E. coli* B, *E. coli* χ 1776 (ATCC No. 31537) as well as *E. coli* W3110 (F-, lambda-, prototrophic, ATCC No. 273325); bacilli such as *Bacillus subtilis*; and other enterobacteriaceae such as *Salmonella typhimurium*, *Serratia marcescens*, and various *Pseudomonas* species.

15

In general, plasmid vectors containing replicon and control sequences that are derived from species compatible with the host cell are used in connection with these hosts. The vector ordinarily carries a replication site, as well as marking sequences that are capable of providing phenotypic selection in transformed cells. For example, *E. coli* is often transformed using pBR322, a plasmid derived from an *E. coli* species. Plasmid pBR322 contains genes for ampicillin and tetracycline resistance and thus provides easy means for identifying transformed cells. The pBR322 plasmid, or other microbial plasmid or phage must also contain, or be modified to contain, promoters that can be used by the microbial organism for expression of its own proteins.

25

In addition, phage vectors containing replicon and control sequences that are compatible with the host microorganism can be used as transforming vectors in connection with these hosts. For example, the phage lambda GEMTM-11 may be utilized in making a recombinant phage vector that can be used to transform host cells, such as *E. coli* LE392.

30

Further useful vectors include pIN vectors (Inouye *et al.*, 1985); and pGEX vectors, for use in generating glutathione *S*-transferase (GST) soluble fusion proteins for later purification and separation or cleavage. Other suitable fusion proteins are those with β -galactosidase, ubiquitin, or the like.

35

5 Promoters that are most commonly used in recombinant DNA construction include the β -lactamase (penicillinase), lactose and tryptophan (*trp*) promoter systems. While these are the most commonly used, other microbial promoters have been discovered and utilized, and details concerning their nucleotide sequences have been published, enabling those of skill in the art to ligate them functionally with plasmid vectors.

10

For expression in *Saccharomyces*, the plasmid YRp7, for example, is commonly used (Stinchcomb *et al.*, 1979; Kingsman *et al.*, 1979; Tschemper *et al.*, 1980). This plasmid contains the *trp1* gene, which provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example ATCC No. 44076 or PEP4-1 (Jones, 1977). The
15 presence of the *trp1* lesion as a characteristic of the yeast host cell genome then provides an effective environment for detecting transformation by growth in the absence of tryptophan.

Suitable promoting sequences in yeast vectors include the promoters for 3-phosphoglycerate kinase (Hitzeman *et al.*, 1980) or other glycolytic enzymes (Hess *et al.*,
20 1968; Holland *et al.*, 1978), such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase. In constructing suitable expression plasmids, the termination sequences associated with these genes are also ligated into the expression vector 3' of the
25 sequence desired to be expressed to provide polyadenylation of the mRNA and termination.

Other suitable promoters, which have the additional advantage of transcription controlled by growth conditions, include the promoter region for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism,
30 and the aforementioned glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization.

In addition to micro-organisms, cultures of cells derived from multicellular organisms may also be used as hosts. In principle, any such cell culture is workable, whether from
35 vertebrate or invertebrate culture. In addition to mammalian cells, these include insect cell systems infected with recombinant virus expression vectors (*e.g.*, baculovirus); and plant cell

5 systems infected with recombinant virus expression vectors (*e.g.*, cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (*e.g.*, Ti plasmid) containing one or more coding sequences.

10 In a useful insect system, *Autographa californica* nuclear polyhidrosis virus (AcNPV) is used as a vector to express foreign genes. The virus grows in *Spodoptera frugiperda* cells. The isolated nucleic acid coding sequences are cloned into non-essential regions (for example the polyhedron gene) of the virus and placed under control of an AcNPV promoter (for example, the polyhedron promoter). Successful insertion of the coding sequences results in the inactivation of the polyhedron gene and production of non-occluded recombinant virus (*i.e.*,
15 virus lacking the proteinaceous coat coded for by the polyhedron gene). These recombinant viruses are then used to infect *Spodoptera frugiperda* cells in which the inserted gene is expressed (*e.g.*, U.S. Patent No. 4,215,051).

20 Examples of useful mammalian host cell lines are VERO and HeLa cells, Chinese hamster ovary (CHO) cell lines, WI38, BHK, COS-7, 293, HepG2, NIH3T3, RIN and MDCK cell lines. In addition, a host cell may be chosen that modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (*e.g.*, glycosylation) and processing (*e.g.*, cleavage) of protein products may be important for the function of the encoded protein.

25 Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. Expression vectors for use in mammalian cells ordinarily include an origin of
30 replication (as necessary), a promoter located in front of the gene to be expressed, along with any necessary ribosome binding sites, RNA splice sites, polyadenylation site, and transcriptional terminator sequences. The origin of replication may be provided either by construction of the vector to include an exogenous origin, such as may be derived from SV40 or other viral (*e.g.*, Polyoma, Adeno, VSV, BPV) source, or may be provided by the host cell
35 chromosomal replication mechanism. If the vector is integrated into the host cell chromosome, the latter is often sufficient.

5

The promoters may be derived from the genome of mammalian cells (*e.g.*, metallothionein promoter) or from mammalian viruses (*e.g.*, the adenovirus late promoter; the vaccinia virus 7.5K promoter). Further, it is also possible, and may be desirable, to utilize promoter or control sequences normally associated with the desired gene sequence, provided
10 such control sequences are compatible with the host cell systems.

Specific initiation signals may also be required for efficient translation of the claimed isolated nucleic acid coding sequences. These signals include the ATG initiation codon and adjacent sequences. Exogenous translational control signals, including the ATG initiation
15 codon, may additionally need to be provided. One of ordinary skill in the art would readily be capable of determining this need and providing the necessary signals. It is well known that the initiation codon must be in-frame (or in-phase) with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The
20 efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements or transcription terminators (Bittner *et al.*, 1987).

In eukaryotic expression, one will also typically desire to incorporate into the transcriptional unit an appropriate polyadenylation site (*e.g.*, 5'-AATAAA-3') if one was not
25 contained within the original cloned segment. Typically, the poly A addition site is placed about 30 to 2000 nucleotides "downstream" of the termination site of the protein at a position prior to transcription termination.

For long-term, high-yield production of recombinant proteins, stable expression is
30 preferred. For example, cell lines that stably express constructs encoding proteins may be engineered. Rather than using expression vectors that contain viral origins of replication, host cells can be transformed with vectors controlled by appropriate expression control elements (*e.g.*, promoter, enhancer, sequences, transcription terminators, polyadenylation sites, *etc.*), and a selectable marker. Following the introduction of foreign DNA, engineered cells may be
35 allowed to grow for 1-2 days in an enriched medium, and then are switched to a selective medium. The selectable marker in the recombinant plasmid confers resistance to the selection

- 5 and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci, which in turn can be cloned and expanded into cell lines.

It is contemplated that the nucleic acids of the invention may be "overexpressed", *i.e.*, expressed in increased levels relative to its natural expression in human cells, or even relative to the expression of other proteins in the recombinant host cell. Such overexpression may be assessed by a variety of methods, including radio-labeling and/or protein purification. However, simple and direct methods are preferred, for example, those involving SDS/PAGE and protein staining or western blotting, followed by quantitative analyses, such as densitometric scanning of the resultant gel or blot. A specific increase in the level of the recombinant protein or peptide in comparison to the level in natural human cells is indicative of overexpression, as is a relative abundance of the specific protein in relation to the other proteins produced by the host cell and, *e.g.*, visible on a gel.

II. Delivery

- 20 In various embodiments of the invention, the expression construct may comprise a virus or engineered construct derived from a viral genome. The ability of certain viruses to enter cells via receptor-mediated endocytosis and to integrate into the host cell genome and express viral genes stably and efficiently have made them attractive candidates for the transfer of foreign genes into mammalian cells (Ridgeway, 1988; Nicolas and Rubenstein, 1988; Baichwal and Sugden, 1986; Temin, 1986). The first viruses used as vectors were DNA viruses including the papovaviruses (simian virus 40, bovine papilloma virus, and polyoma) (Ridgeway, 1988; Baichwal and Sugden, 1986) and adenoviruses (Ridgeway, 1988; Baichwal and Sugden, 1986) and adeno-associated viruses. Retroviruses also are attractive gene transfer vehicles (Nicolas and Rubenstein, 1988; Temin, 1986) as are vaccinia virus (Ridgeway, 1988) and adeno-associated virus (Ridgeway, 1988). Such vectors may be used to (i) transform cell lines *in vitro* for the purpose of expressing proteins of interest or (ii) to transform cells *in vitro* or *in vivo* to provide therapeutic polypeptides in a gene therapy scenario. Herpes simplex virus (HSV) is another attractive candidate, especially where neurotropism is desired. HSV also is relatively easy to manipulate and can be grown to high titers. Thus, delivery is less of a problem, both in terms of volumes needed to attain sufficient MOI and in a lessened need for repeat dosings.

5 With the recent recognition of defective hepatitis B viruses, new insight was gained into the structure-function relationship of different viral sequences. *In vitro* studies showed that the virus could retain the ability for helper-dependent packaging and reverse transcription despite the deletion of up to 80% of its genome (Horwich *et al.*, 1990). This suggested that large portions of the genome could be replaced with foreign genetic material. The hepatotropism and persistence (integration) were particularly attractive properties for liver-directed gene transfer. Chang *et al.*, recently introduced the chloramphenicol acetyltransferase (CAT) gene into duck hepatitis B virus genome in the place of the polymerase, surface, and pre-surface coding sequences. It was co-transfected with wild-type virus into an avian hepatoma cell line. Culture media containing high titers of the recombinant virus were used to infect primary duckling hepatocytes. Stable CAT gene expression was detected for at least 24 days after transfection (Chang *et al.*, 1991).

Several non-viral methods for the transfer of expression constructs into cultured mammalian cells also are contemplated by the present invention. These include calcium phosphate precipitation (Graham and Van Der Eb, 1973; Chen and Okayama, 1987; Rippe *et al.*, 1990) DEAE-dextran (Gopal, 1985), electroporation (Tur-Kaspa *et al.*, 1986; Potter *et al.*, 1984), direct microinjection (Harland and Weintraub, 1985), DNA-loaded liposomes (Nicolau and Sene, 1982; Fraley *et al.*, 1979) and lipofectamine-DNA complexes, cell sonication (Fechheimer *et al.*, 1987), gene bombardment using high velocity microprojectiles (Yang *et al.*, 1990), and receptor-mediated transfection (Wu and Wu, 1987; Wu and Wu, 1988). Some of these techniques may be successfully adapted for *in vivo* or *ex vivo* use.

Once the expression construct has been delivered into the cell the nucleic acid encoding the gene of interest may be positioned and expressed at different sites. In certain embodiments, the nucleic acid encoding the gene may be stably integrated into the genome of the cell. This integration may be in the cognate location and orientation via homologous recombination (gene replacement) or it may be integrated in a random, non-specific location (gene augmentation). In yet further embodiments, the nucleic acid may be stably maintained in the cell as a separate, episomal segment of DNA. Such nucleic acid segments or "episomes" encode sequences sufficient to permit maintenance and replication independent of or in synchronization with the

5 host cell cycle. How the expression construct is delivered to a cell and where in the cell the nucleic acid remains is dependent on the type of expression construct employed.

In one embodiment, the expression construct may simply consist of naked recombinant DNA or plasmids. Transfer of the construct may be performed by any of the methods
10 mentioned above which physically or chemically permeabilize the cell membrane. This is particularly applicable for transfer *in vitro* but it may be applied to *in vivo* use as well. Dubensky *et al.*, (1984) successfully injected polyomavirus DNA in the form of calcium phosphate precipitates into liver and spleen of adult and newborn mice demonstrating active viral replication and acute infection. Benvenisty and Neshif (1986) also demonstrated that
15 direct intraperitoneal injection of calcium phosphate-precipitated plasmids results in expression of the transfected genes. It is envisioned that DNA encoding a gene of interest may also be transferred in a similar manner *in vivo* and express the gene product.

Another embodiment of the invention for transferring a naked DNA expression
20 construct or DNA segment into cells may involve particle bombardment. This method depends on the ability to accelerate DNA-coated microprojectiles to a high velocity allowing them to pierce cell membranes and enter cells without killing them (Klein *et al.*, 1987). Several devices for accelerating small particles have been developed. One such device relies on a high voltage discharge to generate an electrical current, which in turn provides the motive force (Yang *et al.*,
25 1990). The microprojectiles used have consisted of biologically inert substances such as tungsten or gold beads.

Selected organs including the liver, skin, and muscle tissue of rats and mice have been bombarded *in vivo* (Yang *et al.*, 1990; Zelenin *et al.*, 1991). This may require surgical exposure
30 of the tissue or cells, to eliminate any intervening tissue between the gun and the target organ, *i.e.*, *ex vivo* treatment. Again, DNA encoding a particular gene may be delivered via this method and still be incorporated by the present invention.

In a further embodiment of the invention, the DNA segment or expression construct
35 may be entrapped in a liposome. Liposomes are vesicular structures characterized by a phospholipid bilayer membrane and an inner aqueous medium. Multilamellar liposomes have

5 multiple lipid layers separated by aqueous medium. They form spontaneously when phospholipids are suspended in an excess of aqueous solution. The lipid components undergo self-rearrangement before the formation of closed structures and entrap water and dissolved solutes between the lipid bilayers (Ghosh and Bachhawat, 1991). Also contemplated are lipofectamine-DNA complexes.

10

Liposome-mediated nucleic acid delivery and expression of DNA *in vitro* has been very successful. Wong *et al.*, (1980) demonstrated the feasibility of liposome-mediated delivery and expression of foreign DNA in cultured chick embryo, HeLa and hepatoma cells. Nicolau *et al.*, (1987) accomplished successful liposome-mediated gene transfer in rats after intravenous
15 injection.

In certain embodiments, the liposome may be complexed with a hemagglutinating virus (HVJ). This has been shown to facilitate fusion with the cell membrane and promote cell entry of liposome-encapsulated DNA (Kaneda *et al.*, 1989). In other embodiments, the liposome
20 may be complexed or employed in conjunction with nuclear non-histone chromosomal proteins (HMG-1) (Kato *et al.*, 1991). In yet further embodiments, the liposome may be complexed or employed in conjunction with both HVJ and HMG-1. In that such expression constructs have been successfully employed in transfer and expression of nucleic acid *in vitro* and *in vivo*, then they are applicable for the present invention. Where a bacterial promoter is employed in the
25 DNA construct, it also will be desirable to include within the liposome an appropriate bacterial polymerase.

Other expression constructs which can be employed to deliver a nucleic acid encoding a particular gene into cells are receptor-mediated delivery vehicles. These take advantage of the
30 selective uptake of macromolecules by receptor-mediated endocytosis in almost all eukaryotic cells. Because of the cell type-specific distribution of various receptors, the delivery can be highly specific (Wu and Wu, 1993).

Receptor-mediated gene targeting vehicles generally consist of two components: a cell
35 receptor-specific ligand and a DNA-binding agent. Several ligands have been used for receptor-mediated gene transfer. The most extensively characterized ligands are

5 asialoorosomucoid (ASOR) (Wu and Wu, 1987) and transferrin (Wagner *et al.*, 1990). Recently, a synthetic neoglycoprotein, which recognizes the same receptor as ASOR, has been used as a gene delivery vehicle (Ferkol *et al.*, 1993; Perales *et al.*, 1994) and epidermal growth factor (EGF) has also been used to deliver genes to squamous carcinoma cells (Myers, EPO 0273085).

10

In other embodiments, the delivery vehicle may comprise a ligand and a liposome. For example, Nicolau *et al.*, (1987) employed lactosyl-ceramide, a galactose-terminal asialganglioside, incorporated into liposomes and observed an increase in the uptake of the insulin gene by hepatocytes. Thus, it is feasible that a nucleic acid encoding a particular gene
15 also may be specifically delivered into a cell type such as lung, epithelial or tumor cells, by any number of receptor-ligand systems with or without liposomes.

In certain embodiments, gene transfer may more easily be performed under *ex vivo* conditions. *Ex vivo* gene therapy refers to the isolation of cells from an organism, the delivery
20 of a nucleic acid into the cells *in vitro*, and then the return of the modified cells back into an organism. This may involve the surgical removal of tissue/organs from an animal or the primary culture of cells and tissues. Anderson *et al.*, U.S. Patent 5,399,346, and incorporated herein in its entirety, disclose *ex vivo* therapeutic methods.

25 F. Oligonucleotide Synthesis

Oligonucleotide synthesis is well known to those of skill in the art. Various different mechanisms of oligonucleotide synthesis have been disclosed in for example, U.S. Patents. 4,659,774, 4,816,571, 5,141,813, 5,264,566, 4,959,463, 5,428,148, 5,554,744, 5,574,146, 5,602,244, each of which is incorporated herein by reference.

30

Phosphoramidite chemistry (Beaucage, and Lyer, 1992) has become by far the most widely used coupling chemistry for the synthesis of oligonucleotides. As is well known to those skilled in the art, phosphoramidite synthesis of oligonucleotides involves activation of nucleoside phosphoramidite monomer precursors by reaction with an activating agent to form
35 activated intermediates, followed by sequential addition of the activated intermediates to the

- 5 growing oligonucleotide chain (generally anchored at one end to a suitable solid support) to form the oligonucleotide product.

Tetrazole is commonly used for the activation of the nucleoside phosphoramidite monomers. Tetrazole has an acidic proton which presumably protonates the basic nitrogen of
10 the diisopropylamino phosphine group, thus making the diisopropylamino group a leaving group. The negatively charged tetrazolium ion then makes an attack on the trivalent phosphorous, forming a transient phosphorous tetrazolide species. The 5'-OH group of the solid support bound nucleoside then attacks the active trivalent phosphorous species, resulting in the formation of the internucleotide linkage. The trivalent phosphorous is finally oxidized to
15 the pentavalent phosphorous. The US patents listed above describe other activators and solid supports for oligonucleotide synthesis.

High throughput oligonucleotide synthesis can be achieved using a synthesizer. The Genome Science and Technology Center, as one aspect of the automation development effort,
20 recently developed a high throughput large scale oligonucleotide synthesizer. This instrument, denoted the MERMADE, is based on a 96-well plate format and uses robotic control to carry out parallel synthesis on 192 samples (2 96-well plates). This device has been variously described in the literature and in presentations, is generally available in the public domain (licensed from the University of Texas and available on contract from Avantec). The device
25 has gone through various generations with differing operating parameters.

The device may be used to synthesize 192 oligonucleotides simultaneously with 99% success. It has virtually 100% success for oligomers less than 60 bp; operates at 20 mM synthesis levels, and gives a product yield of >99% complete synthesis. Using these systems
30 the inventor has synthesized over 10,000 oligomers used for sequencing, PCRTM amplification and recombinant DNA applications. For most uses, including cloning, synthesis success is sufficient such that post synthesis purification is not required.

Once the genome has been synthesized using the methods of the present invention it
35 may be necessary to screen the sequences for analysis of function. Specifically contemplated by the present inventor are chip-based DNA technologies such as those described by Hacia *et*

5 *al.* (1996) and Shoemaker *et al.* (1996). Briefly, these techniques involve quantitative methods for analyzing large numbers of genes rapidly and accurately. By tagging genes with oligonucleotides or using fixed probe arrays, one can employ chip technology to segregate target molecules as high density arrays and screen these molecules on the basis of hybridization. See also Pease *et al.* (1994); Fodor *et al.* (1991).

10

The use of combinatorial synthesis and high throughput screening assays are well known to those of skill in the art, *e.g.* 5,807,754; 5,807,683; 5,804,563; 5,789,162; 5,783,384; 5,770,358; 5,759,779; 5,747,334; 5,686,242; 5,198,346; 5,738,996; 5,733,743; 5,714,320; 5,663,046 (each specifically incorporated herein by reference). These patents teach various
15 aspects of the methods and compositions involved in the assembly and activity analyses of high density arrays of different polysubunits (polynucleotides or polypeptides). As such it is contemplated that the methods and compositions described in the patents listed above may be useful in assay the activity profiles of the compositions of the present invention.

20 The present invention produces a replication competent polynucleotide. Viruses are naturally occurring replication competent pieces of DNA, to the extent that disclosure regarding viruses may be useful in the context of the present invention, the following is a disclosure of viruses. Researchers note that viruses have evolved to be able to deliver their DNA to various host tissues despite the human body's various defensive mechanisms. For this reason,
25 numerous viral vectors have been designed by researchers seeking to create vehicles for therapeutic gene delivery. Some of the types of viruses that have been engineered are listed below.

II. Adenovirus

30 Adenovirus is a 36 kB, linear, double-strained DNA virus that allows substitution of large pieces of adenoviral DNA with foreign sequences up to 7 kB (Grunhaus and Horwitz, 1992). Adenovirus DNA does not integrate into the host cell chromosomal because adenoviral DNA can replicate in an episomal manner. Also, adenoviruses are structurally stable, and no genome rearrangement has been detected after extensive amplification. Adenovirus can infect
35 virtually all epithelial cells regardless of their cell cycle stage. This means that adenovirus can infect non-dividing cells. So far, adenoviral infection appears to be linked only to mild disease

5 such as acute respiratory disease in humans. This group of viruses can be obtained in high titers, e.g., 10^9 - 10^{11} plaque-forming units per ml, and they are highly infective.

Both ends of the viral genome contain 100-200 base pair inverted repeats (ITRs), which are *cis* elements necessary for viral DNA replication and packaging. The early (E) and late (L) regions of the genome contain different transcription units that are divided by the onset of viral DNA replication. The E1 region (E1A and E1B) encodes proteins responsible for the regulation of transcription of the viral genome and a few cellular genes. The expression of the E2 region (E2A and E2B) results in the synthesis of the proteins for viral DNA replication. These proteins are involved in DNA replication, late gene expression and host cell shut-off (Renan, 1990). The products of the late genes, including the majority of the viral capsid proteins, are expressed only after significant processing of a single primary transcript issued by the major late promoter (MLP). The MLP, (located at 16.8 m.u.) is particularly efficient during the late phase of infection, and all the mRNA's issued from this promoter possess a 5'-tripartite leader (TPL) sequence which makes them preferred mRNA's for translation.

20

The E3 region encodes proteins that appears to be necessary for efficient lysis of Ad infected cells as well as preventing TNF-mediated cytolysis and CTL mediated lysis of infected cells. In general, the E4 region encodes is believed to encode seven proteins, some of which activate the E2 promoter. It has been shown to block host mRNA transport and enhance transport of viral RNA to cytoplasm. Further the E4 product is in part responsible for the decrease in early gene expression seen late in infection. E4 also inhibits E1A and E4 (but not E1B) expression during lytic growth. Some E4 proteins are necessary for efficient DNA replication however the mechanism for this involvement is unknown. E4 is also involved in post-transcriptional events in viral late gene expression; *i.e.*, alternative splicing of the tripartite leader in lytic growth. Nevertheless, E4 functions are not absolutely required for DNA replication but their lack will delay replication. Other functions include negative regulation of viral DNA synthesis, induction of sub-nuclear reorganization normally seen during adenovirus infection, and other functions that are necessary for viral replication, late viral mRNA accumulation, and host cell transcriptional shut off.

30

5

II. Retroviruses

The retroviruses are a group of single-stranded RNA viruses characterized by an ability to convert their RNA to double-stranded DNA to infected cells by a process of reverse-transcription (Coffin, 1990). The resulting DNA then stably integrates into cellular chromosomes as a provirus and directs synthesis of viral proteins. The integration results in the retention of the viral gene sequences in the recipient cell and its descendants. The retroviral genome contains three genes, gag, pol, and env that code for capsid proteins, polymerase enzyme, and envelope components, respectively. A sequence found upstream from the gag gene, termed ψ components is constructed (Mann *et al.*, 1983). When a recombinant plasmid containing a human cDNA, together with the retroviral LTR and ψ sequences is introduced into this cell line (by calcium phosphate precipitation for example), the ψ sequence allows the RNA transcript of the recombinant plasmid to be packaged into viral particles, which are then secreted into the culture media (Nicolas and Rubenstein, 1988; Temin, 1986; Mann *et al.*, 1983). The media containing the recombinant retroviruses is then collected, optionally concentrated, and used for gene transfer. Retroviral vectors are able to infect a broad variety of cell types. However, integration requires the division of host cells (Paskind *et al.*, 1975).

The retrovirus family includes the subfamilies of the oncoviruses, the lentiviruses and the spumaviruses. Two oncoviruses are Moloney murine leukemia virus (MMLV) and feline leukemia virus (FeLV). The lentiviruses include human immunodeficiency virus (HIV), simian immunodeficiency virus (SIV) and feline immunodeficiency virus (FIV). Among the murine viruses such as MMLV there is a further classification. Murine viruses may be ecotropic, xenotropic, polytropic or amphotropic. Each class of viruses target different cell surface receptors in order to initiate infection.

30

Further advances in retroviral vector design and concentration methods have allowed production of amphotropic and xenotropic viruses with titers of 10^8 to 10^9 cfu/ml (Bowles *et al.*, 1996; Irwin *et al.*, 1994; Jolly, 1994; Kitten *et al.*, 1997).

35

Replication defective recombinant retroviruses are not acute pathogens in primates (Chowdhury *et al.*, 1991). They have been successfully applied in cell culture systems to

5 transfer the CFTR gene and generate cAMP-activated Cl⁻ secretion in a variety of cell types including human airway epithelia (Drumm *et al.*, 1990, Olsen *et al.*, 1992; Anderson *et al.*, 1991; Olsen *et al.*, 1993). While there is evidence of immune responses to the viral gag and env proteins, this does not prevent successful readministration of vector (McCormack *et al.*, 1997). Further, since recombinant retroviruses have no expressed gene products other than the
10 transgene, the risk of a host inflammatory response due to viral protein expression is limited (McCormack *et al.*, 1997). As for the concern about insertional mutagenesis, to date there are no examples of insertional mutagenesis arising from any human trial with recombinant retroviral vectors.

15 More recently, hybrid lentivirus vectors have been described combining elements of human immunodeficiency virus (HIV) (Naldini *et al.*, 1996) or feline immunodeficiency virus (FIV) (Poeschla *et al.*, 1998) and MMLV. These vectors transduce nondividing cells in the CNS (Naldini *et al.*, 1996; Blomer *et al.*, 1997), liver (Kafri *et al.*, 1997), muscle (Kafri *et al.*, 1997) and retina (Miyoshi *et al.*, 1997). However, a recent report in xenograft models of
20 human airway epithelia suggests that in well-differentiated epithelia, gene transfer with VSV-G pseudotyped HIV-based lentivirus is inefficient (Goldman *et al.*, 1997).

III. Adeno-Associated Virus

In addition, AAV possesses several unique features that make it more desirable than the
25 other vectors. Unlike retroviruses, AAV can infect non-dividing cells; wild-type AAV has been characterized by integration, in a site-specific manner, into chromosome 19 of human cells (Kotin and Berns, 1989; Kotin *et al.*, 1990; Kotin *et al.*, 1991; Samulski *et al.*, 1991); and AAV also possesses anti-oncogenic properties (Ostrove *et al.*, 1981; Berns and Giraud, 1996). Recombinant AAV genomes are constructed by molecularly cloning DNA sequences of interest
30 between the AAV ITRs, eliminating the entire coding sequences of the wild-type AAV genome. The AAV vectors thus produced lack any of the coding sequences of wild-type AAV; yet retain the property of stable chromosomal integration and expression of the recombinant genes upon transduction both *in vitro* and *in vivo* (Berns, 1990; Berns and Bohensky, 1987; Bertran *et al.*, 1996; Kearns *et al.*, 1996; Ponnazhagan *et al.*, 1997a). Until recently, AAV was
35 believed to infect almost all cell types, and even cross species barriers. However, it now has

5 been determined that AAV infection is receptor-mediated (Ponnazhagan *et al.*, 1996; Mizukami *et al.*, 1996).

AAV utilizes a linear, single-stranded DNA of about 4700 base pairs. Inverted terminal repeats flank the genome. Two genes are present within the genome, giving rise to a number of
10 distinct gene products. The first, the *cap* gene, produces three different virion proteins (VP), designated VP-1, VP-2 and VP-3. The second, the *rep* gene, encodes four non-structural proteins (NS). One or more of these *rep* gene products is responsible for transactivating AAV transcription. The sequence of AAV is provided by Srivastava *et al.* (1983), and in U.S. Patent 5,252,479 (entire text of which is specifically incorporated herein by reference).

15

The three promoters in AAV are designated by their location, in map units, in the genome. These are, from left to right, p5, p19 and p40. Transcription gives rise to six transcripts, two initiated at each of three promoters, with one of each pair being spliced. The splice site, derived from map units 42-46, is the same for each transcript. The four non-
20 structural proteins apparently are derived from the longer of the transcripts, and three virion proteins all arise from the smallest transcript.

AAV is not associated with any pathologic state in humans. Interestingly, for efficient replication, AAV requires "helping" functions from viruses such as herpes simplex virus I and
25 II, cytomegalovirus, pseudorabies virus and, of course, adenovirus. The best characterized of the helpers is adenovirus, and many "early" functions for this virus have been shown to assist with AAV replication. Low level expression of AAV *rep* proteins is believed to hold AAV structural expression in check, and helper virus infection is thought to remove this block.

30

IV. Vaccinia Virus

Vaccinia viruses are a genus of the poxvirus family. Vaccinia virus vectors have been used extensively because of the ease of their construction, relatively high levels of expression obtained, wide host range and large capacity for carrying DNA. Vaccinia contains a linear, double-stranded DNA genome of about 186 kB that exhibits a marked "A-T" preference.
35 Inverted terminal repeats of about 10.5 kB flank the genome. The majority of essential genes appear to map within the central region, which is most highly conserved among poxviruses.

- 5 Estimated open reading frames in vaccinia virus number from 150 to 200. Although both strands are coding, extensive overlap of reading frames is not common. U.S. Patent 5,656,465 (specifically incorporated by reference) describes *in vivo* gene delivery using pox viruses.

V. Papovavirus

- 10 The papovavirus family includes the papillomaviruses and the polyomaviruses. The polyomaviruses include Simian Virus 40 (SV40), polyoma virus and the human polyomaviruses BKV and JCV. Papillomaviruses include the bovine and human papillomaviruses. The genomes of polyomaviruses are circular DNAs of a little more than 5000 bases. The predominant gene products are three virion proteins (VP1-3) and Large T and
15 Small T antigens. Some have an additional structural protein, the agnoprotein, and others have a Middle T antigen. Papillomaviruses are somewhat larger, approaching 8 kB

- Little is known about the cellular receptors for polyomaviruses, but polyoma infection can be blocked by treating with sialidase. SV40 will still infect sialidase-treated cells, but JCV
20 cannot hemagglutinate cells treated with sialidase. Because interaction of polyoma VP1 with the cell surface activates *c-myc* and *c-fos*, it has been hypothesized that the virus receptor may have some properties of a growth factor receptor. Papillomaviruses are specifically tropic for squamous epithelia, though the specific receptor has not been identified.

25 VI. Paramyxovirus

- The paramyxovirus family is divided into three genera: paramyxovirus, morbillivirus and pneumovirus. The paramyxovirus genus includes the mumps virus and Sendai virus, among others, while the morbilliviruses include the measles virus and the pneumoviruses include respiratory syncytial virus (RSV). Paramyxovirus genomes are RNA based and contain
30 a set of six or more genes, covalently linked in tandem. The genome is something over 15 kB in length. The viral particle is 150-250 nm in diameter, with "fuzzy" projections or spikes protruding therefrom. These are viral glycoproteins that help mediate attachment and entry of the virus into host cells.

- 35 A specialized series of proteins are involved in the binding and entry of paramyxoviruses. Attachment in *Paramyxoviruses* and *Morbilliviruses* is mediated by glycoproteins that bind to

5 sialic acid-containing receptors. Other proteins anchor the virus by embedding hydrophobic regions in the lipid bilayer of the cell's surface, and exhibit hemagglutinating and neuraminidase activities. In *Pneumoviruses*, the glycoprotein is heavily glycosylated with *O*-glycosidic bonds. This molecule lacks the exhibit hemagglutinating and neuraminidase activities of its relatives.

10 VII. Herpesvirus.

Because herpes simplex virus (HSV) is neurotropic, it has generated considerable interest in treating nervous system disorders. Moreover, the ability of HSV to establish latent infections in non-dividing neuronal cells without integrating in to the host cell chromosome or otherwise altering the host cell's metabolism, along with the existence of a promoter that is
15 active during latency makes HSV an attractive vector. And though much attention has focused on the neurotropic applications of HSV, this vector also can be exploited for other tissues given its wide host range.

Another factor that makes HSV an attractive vector is the size and organization of the
20 genome. Because HSV is large, incorporation of multiple genes or expression cassettes is less problematic than in other smaller viral systems. In addition, the availability of different viral control sequences with varying performance (temporal, strength, etc.) makes it possible to control expression to a greater extent than in other systems. It also is an advantage that the virus has relatively few spliced messages, further easing genetic manipulations.

25 HSV also is relatively easy to manipulate and can be grown to high titers. Thus, delivery is less of a problem, both in terms of volumes needed to attain sufficient MOI and in a lessened need for repeat dosings. For a review of HSV as a gene therapy vector, see Glorioso *et al.* (1995).

30 HSV, designated with subtypes 1 and 2, are enveloped viruses that are among the most common infectious agents encountered by humans, infecting millions of human subjects worldwide. The large, complex, double-stranded DNA genome encodes for dozens of different gene products, some of which derive from spliced transcripts. In addition to virion and
35 envelope structural components, the virus encodes numerous other proteins including a

- 5 protease, a ribonucleotides reductase, a DNA polymerase, a ssDNA binding protein, a helicase/primase, a DNA dependent ATPase, a dUTPase and others.

HSV genes form several groups whose expression is coordinately regulated and sequentially ordered in a cascade fashion (Honess and Roizman, 1974; Honess and Roizman
10 1975; Roizman and Sears, 1995). The expression of α genes, the first set of genes to be expressed after infection, is enhanced by the virion protein number 16, or α -transducing factor (Post *et al.*, 1981; Batterson and Roizman, 1983; Campbell *et al.*, 1983). The expression of β genes requires functional α gene products, most notably ICP4, which is encoded by the α 4 gene (DeLuca *et al.*, 1985). γ genes, a heterogeneous group of genes encoding largely virion
15 structural proteins, require the onset of viral DNA synthesis for optimal expression (Holland *et al.*, 1980).

In line with the complexity of the genome, the life cycle of HSV is quite involved. In addition to the lytic cycle, which results in synthesis of virus particles and, eventually, cell
20 death, the virus has the capability to enter a latent state in which the genome is maintained in neural ganglia until some as of yet undefined signal triggers a recurrence of the lytic cycle. Avirulent variants of HSV have been developed and are readily available for use in gene therapy contexts (U.S. Patent 5,672,344).

25 G. Examples

The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its
30 practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.

5

EXAMPLE 1**Combinatoric gene assembly**

The inventor has developed a strategy of oligomer assembly into larger DNA molecules denoted combinatoric assembly. The procedure is carried out as follows: one may design a plasmid using one of a number of commercial or public domain computer programs to contain the genes, promoters, drug selection, origin of replication, etc. required. SynGene v.2.0 is a program that generates a list of overlapping oligonucleotides sufficient to reassemble the gene or plasmid (see FIG. 7A-FIG. 7G). For instance, for a 5000 bp gene, SynGene 2.0 can generate two lists of 100 component 50 mers from one strand and 100 component 50 mers from the complementary strand such that each pair of oligomers will overlap by 25 base pairs. The program checks the sequence for repeats and produces a MERMADE input file which directly programs the oligonucleotide synthesizer. The synthesizer produces two sets of 96-well plates containing the complementary oligonucleotides. A SynGene program is depicted in FIG. 7. This program is designed to break down a designer gene or genome into oligonucleotides for synthesis. The program is for the complete synthetic designer gene and is based upon an original program for formatting DNA sequences written by Dr. Glen Evans.

Combinatoric assembly is best carried out using a programmable robotic workstation such as a Beckman Biomek 2000. In short, pairs of oligomers which overlap are mixed and annealed. Following annealing, a smaller set of duplex oligomers is generated. These are again paired and annealed, forming a smaller set of larger oligomers. Sequentially, overlapping oligomers are allowed to anneal until the entire reassembly is completed. Annealing may be carried out in the absence of ligase, or each step may be followed by ligation. In one configuration, oligomers are annealed in the presence of topoisomerase 2, which does not require 5' phosphorylation of the oligomer, occurs at room temperature, and is a rapid (5 minute) reaction as opposed to 12 h ligation at 12°. Following the complete assembly, the resulting DNA molecule can be used for its designed purpose, usually transformation into a bacterial host for replication. The steps in this cycle are outlined in FIG. 3.

This approach has a major advantage over traditional recombinant DNA based cloning. While it is technically feasible to make virtually any modification or mutation in existing DNA molecules, the effort required, as well as the high technical skill, make some constructions

- 5 difficult or tedious. This method, while having been used for many years, is not applicable to automated gene cloning or large scale creation or entirely novel DNA sequences.

EXAMPLE 2

Production of Artificial Genes

10

In one example, the present invention will produce a known gene of about 1000 base pairs in length by the following method. A set of oligonucleotides, each of 50 bases, is generated such that the entire plus strand of the gene is represented. A second set of oligonucleotides, also comprised of 50-mers, is generated for the minus strand. This set is
15 designed, however, such that complementary pairing with the first and second sets results in overlap of "paired" sequences, *i.e.*, each oligonucleotide of the first set is complementary with regions from two oligonucleotides of the second set (with the possible exception of the terminal oligonucleotides). The region of overlap is set at 30 bases, leaving a 20 base pair overhang for each pair. The first and said second set of oligonucleotides is annealed in a single mixture and
20 treated with a ligating enzyme.

In another example, the gene to be synthesized is about 5000 base pairs. Each set of oligonucleotides is made up of fifty 100-mers with overlapping regions, of complementary oligonucleotides, of 75 bases, leaving 25 base "sticky ends." In this embodiment, the 5'
25 terminal oligonucleotide of the first oligonucleotide set is annealed with the 3' terminal oligonucleotide of the second set to form a first annealed product, then the next most 5' terminal oligonucleotide of the first set is annealed with the first annealed product to form a second annealed product, and the process is repeated until all oligonucleotides of said first and said second sets have been annealed. Ligation of the products may occur between steps or at
30 the conclusion of all hybridizations.

In a third example, a gene of 100,000 bp is synthesized from one thousand 100-mers. Again, the overlap between "pairs" of plus and minus oligonucleotides is 75 bases, leaving a 25 base pair overhang. In this method, a combinatorial approach is used where corresponding
35 pairs of partially complementary oligonucleotides are hybridized in first step. A second round of hybridization then is undertaken with appropriately complementary pairs of products from

5 the first round. This process is repeated a total of 10 times, each round of hybridization reducing the number of products by half. Ligation of the products then is performed.

EXAMPLE 3

Large scale expression of human gene products

10

Once the human genome has been characterized, functional analysis of the human genome, based upon the complete sequence, will require a variety of approaches to structural, functional and network biology. The approach proposed herein for producing a series of expression constructs representing all potential human gene products and the assembly of sets
15 of bacterial and/or yeast expressing these products will provide an important avenue into the beginnings of functional analysis.

Secondly, the approach described here, when developed to its theoretical optima, will allow the large scale transfer of genes to cell lines or organisms for functional analysis. The
20 long term goal of this concept is the creation of living organisms entirely based on bioinformatics and information processing. Obviously, the knowledge of the complete sequence is not sufficient to appreciate the myriad of biological concepts inherent in life.

EXAMPLE 4

25

Construction of a synthetic plasmid

A DNA molecule was designed using synthetic parts of previously known plasmids. As a demonstration of this technique, plasmid synlux4 was designed. Synlux4 consists of 4800 base pairs of DNA. Within this sequence are included the sequence of lux A and lx B, the A and B components of the luciferase protein from *Vibrio Fisherii*, portions of plasmid pUC19
30 including the origin of replication and replication stability sequences, the promoter and coding sequence for tn9 kanamycin/neomycin phosphotransferase. The sequence was designed on a computer using Microsoft Word and Vector NTI (InforMax, Inc.). The sequence is listed in FIG. 4A-FIG. 4C.

35 Following design, a computer program SynGene 2.0 was used to break the sequence down into components consisting of overlapping 50-mer oligonucleotides. From the 4800 base

5 pair sequence, 192 50-mers were designed. The component oligonucleotides are listed in FIG. 5A-FIG. 5F. These component oligonucleotides were synthesized using a custom 96-well oligonucleotide synthesizer (Rayner, et al.) Genome Research, 8, 741-747 (1998). The component oligonucleotides were produced in two 96-well microtitre plates, each plate holding one set of component oligonucleotides. Thus, plate one held the forward strand oligos and plate
10 2 held the reverse strand oligos.

The oligonucleotides were assembled and ligations carried out using a Biomek 1000 robotic workstation (Beckman). Sequential transfers of oligonucleotides were done by pipetting from one well to a second well of the plate and a ligation reaction carried out using T4
15 ligase. The pattern of assembly is delineated in FIG. 6A-FIG. 6B.

Following assembly, the resulting ligation mix was used to transform competent *E. coli* strain DH5a. The transformation mix was plated on LB plates containing 25 µg/ml kanamycin sulfate, and recombinant colonies obtained. The resulting recombinant clones were isolated,
20 cloned, and DNA prepared. The DNA was analyzed on 1% agarose gels in order detect recombinant molecules. Clones were shown to contain the expected 4800 base pair plasmid containing lux A and B genes.

* * *

25 All of the compositions and/or methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and/or methods and in the steps or in the sequence of steps of the method
30 described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as
35 defined by the appended claims.

REFERENCES

The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference.

- Anderson *et al.* US 5,399,346, 1995.
- 10 Anderson *et al.*, *Science*, 253:202-205, 1991.
- Baichwal and Sugden, "Vectors for gene transfer derived from animal DNA viruses: Transient and stable expression of transferred genes," In: *Gene Transfer*, Kucherlapati (ed.), New York, Plenum Press, pp. 117-148, 1986.
- Batterson and Roizman, *J. Virol.*, 46:371-377, 1983.
- 15 Beaucage, and Lyer, *Tetrahedron*, 48:2223-2311, 1992
- Benvenisty and Neshif, "Direction introduction of genes into rats and expression of the genes," *Proc. Nat. Acad. Sci. USA*, 83:9551-9555, 1986.
- Berns and Bohenzky, *Adv. Virus Res.*, 32:243-307, 1987.
- Bertran, *et al.*, *J Virol.*, 70(10):6759-6766, 1996.
- 20 Bittner *et al.*, *Methods in Enzymol*, 153:516-544, 1987.
- Blomer *et al.*, Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. *J. Virol.* 71:6641-6649, 1997
- Bowles *et al.*, *Hum. Gene Ther.*, 7:1735-1742, 1996.
- Chang *et al.*, "Foreign gene delivery and expression in hepatocytes using a hepatitis B virus vector," *Hepatology*, 14:124A, 1991.
- 25 Chen and Okayama, "High-efficiency transfection of mammalian cells by plasmid DNA," *Mol. Cell Biol.*, 7:2745-2752, 1987.
- Coffin, "Retroviridae and their replication," In: *Virology*, Fields, Knipe (ed.), New York: Raven Press, pp. 1437-1500, 1990.
- 30 Coffin, In: *Virology*, ed., New York: Raven Press, pp. 1437-1500, 1990.
- Colberre-Garapin *et al.*, *J. Mol. Biol.*, 150:1, 1981.

- Couch *et al.*, "Immunization with types 4 and 7 adenovirus by selective infection of the intestinal tract," *Am. Rev. Resp. Dis.*, 88:394-403, 1963.
- Coupar *et al.*, "A general method for the construction of recombinant vaccinia virus expressing multiple foreign genes," *Gene*, 68:1-10, 1988.
- 5 Davey *et al.*, EPO No. 329 822.
- DeLuca *et al.*, *J. Virol.*, 56:558-570, 1985.
- Drumm *et al.*, *Cell*, 62:1227-1233, 1990.
- Dubensky *et al.*, "Direct transfection of viral and plasmid DNA into the liver or spleen of mice," *Proc. Nat. Acad. Sci. USA*, 81:7529-7533, 1984.
- 10 Fechheimer *et al.*, "Transfection of mammalian cells with plasmid DNA by scrape loading and sonication loading," *Proc. Natl. Acad. Sci. USA*, 84:8463-8467, 1987.
- Ferkol *et al.*, "Regulation of the phosphoenolpyruvate carboxykinase/human factor IX gene introduced into the livers of adult rats by receptor-mediated gene transfer," *FASEB J.*, 7:1081-1091, 1993.
- 15 Fraley *et al.*, "Entrapment of a bacterial plasmid in phospholipid vesicles: Potential for gene transfer," *Proc. Natl. Acad. Sci. USA*, 76:3348-3352, 1979.
- Freifelder, *Physical Biochemistry Applications to Biochemistry and Molecular Biology*, 2nd ed. Wm. Freeman and Co., New York, NY, 1982.
- Friedmann, "Progress toward human gene therapy," *Science*, 244:1275-1281, 1989.
- 20 Frohman, In: *PCR™ Protocols: A Guide To Methods And Applications*, Academic Press, N.Y., 1990.
- Ghosh-Choudhury *et al.*, *EMBO J.*, 6:1733-1739, 1987.
- Ghosh and Bachhawat, "Targeting of liposomes to hepatocytes," In: *Liver diseases, targeted diagnosis and therapy using specific receptors and ligands*, Wu, Wu (ed.), New York:,
- 25 Marcel Dekker, pp. 87-104, 1991.
- Gingeras *et al.*, PCT Application WO 88/10315.
- Glorioso *et al.*, *Ann. Rev. Microbiol.*, 49:675-710, 1995.
- Goldman *et al.*, *Hum Gene Ther.* 8(18): 2261-2268, 1997.
- Gomez-Foix *et al.*, "Adenovirus-mediated transfer of the muscle glycogen phosphorylase gene
- 30 into hepatocytes confers altered regulation of glycogen," *J. Biol. Chem.*, 267:25129-25134, 1992.

- Gopal, "Gene transfer method for transient gene expression, stable transfection, and cotransfection of suspension cell cultures," *Mol. Cell Biol.*, 5:1188-1190, 1985.
- Graham and Prevec, "Adenovirus-based expression vectors and recombinant vaccines," *Biotech.*, 20:363-390, 1992.
- 5 Graham and Prevec, "Manipulation of adenovirus vector," *In: Methods in Molecular Biology: Gene Transfer and Expression Protocol*, Clifton and Murray (ed.), NJ, Humana Press, 7:109-128, 1991.
- Graham and Van Der Eb, "A new technique for the assay of infectivity of human adenovirus 5 DNA," *Virology*, 52:456-467, 1973.
- 10 Graham *et al.*, "Characteristics of a human cell line transformed by DNA from human adenovirus type 5," *J. Gen. Virol.*, 36:59-72, 1977.
- Grunhaus and Horwitz, "Adenovirus as cloning vector," *Seminar in Virology*, 3:237-252, 1992.
- Harland and Weintraub, "Translation of mammalian mRNA injected into *Xenopus* oocytes is specifically inhibited by antisense RNA," *J. Cell Biol.*, 101:1094-1099, 1985.
- 15 Hermonat and Muzycska, "Use of adenoassociated virus as a mammalian DNA cloning vector: Transduction of neomycin resistance into mammalian tissue culture cells," *Proc. Nat. Acad. Sci. USA*, 81:6466-6470, 1984.
- Hersdorffer *et al.*, "Efficient gene transfer in live mice using a unique retroviral packaging line," *DNA Cell Biol.*, 9:713-723, 1990.
- 20 Herz and Gerard, "Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice," *Proc. Natl. Acad. Sci. USA* 90:2812-2816, 1993.
- Hess *et al.*, *J. Adv. Enzyme Reg.*, 7:149, 1968.
- Hitzeman *et al.*, *J. Biol. Chem.*, 255:2073, 1980.
- 25 Holland *et al.*, *Biochemistry*, 17:4900, 1978.
- Holland *et al.*, *Virology*, 101:10-18, 1980.
- Honess and Roizman, *J. Virol.*, 14:8-19, 1974.
- Honess and Roizman, *J. Virol.*, 16:1308-1326, 1975
- Horwich *et al.*, "Synthesis of hepadenovirus particles that contain replication-defective duck hepatitis B virus genomes in cultured HuH7 cells," *J. Virol.*, 64:642-650, 1990.
- 30 Innis *et al.*, *PCR™ Protocols*, Academic Press, Inc., San Diego CA, 1990.
- Inouye *et al.*, *Nucleic Acids Res.*, 13: 3101-3109, 1985.

- Irwin et al., *J. Virol.*, 68:5036-5044, 1994.
- Johnson et al., "Peptide Turn Mimetics" IN: *Biotechnology And Pharmacy*, Pezzuto et al., (eds.), Chapman and Hall, New York, 1993.
- Jolly, "Viral vector systems for gene therapy," *Can. Gene Ther.*, 1:51-64, 1994.
- 5 Jones and Shenk, "Isolation of deletion and substitution mutants of adenovirus type 5," *Cell*, 13:181-188, 1978.
- Jones, *Genetics*, 85: 12, 1977.
- Kafri et al., Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. *Nat. Genet.* 17:314-317, 1997.
- 10 Kaneda et al., "Increased expression of DNA cointroduced with nuclear protein in adult rat liver," *Science*, 243:375-378, 1989.
- Karlsson et al., *EMBO J.*, 5:2377-2385, 1986.
- Kato et al., "Expression of hepatitis β virus surface antigen in adult rat liver," *J. Biol. Chem.*, 266:3361-3364, 1991.
- 15 Kearns et al., *Gene Ther.*, 3:748-755, 1996.
- Kingsman et al., *Gene*, 7: 141, 1979.
- Kitten et al. *Hum. Gene Ther.*, 8:1491-1494, 1997.
- Klein et al., "High-velocity microprojectiles for delivering nucleic acids into living cells," *Nature*, 327:70-73, 1987.
- 20 Kotin and Berns, *Virol.*, 170:460-467, 1989.
- Kotin et al., *Genomics*, 10:831-834, 1991.
- Kotin et al., *Proc. Natl. Acad. Sci. USA*, 87:2211-2215, 1990.
- Kwoh et al., *Proc. Nat. Acad. Sci. USA*, 86:1173, 1989.
- Kyte and Doolittle, "A simple method for displaying the hydropathic character of a protein," *J. Mol. Biol.*, 157(1):105-132, 1982.
- 25 Le Gal La Salle et al., "An adenovirus vector for gene transfer into neurons and glia in the brain," *Science*, 259:988-990, 1993.
- Livrero et al., *Gene*, 101:195-202, 1991.
- Lishanski et al., *Proc. Nat'l. Acad. Sci USA.*, 91:2674-2678, (1994)
- 30 Lowy et al., *Cell*, 22: 817, 1980.
- Macejak and Sarnow, *Nature*, 353:90-94, 1991.

- Mann *et al.*, "Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus," *Cell*, 33:153-159, 1983.
- Mann *et al.*, *Cell*, 33:153-159, 1983.
- Markowitz *et al.*, "A safe packaging line for gene transfer: Separating viral genes on two different plasmids," *J. Virol.*, 62:1120-1124, 1988.
- 5 McCormack *et al.* *Hum. Gene Ther.* 8: 1263-1273, 1997.
- Miller *et al.*, PCT Application WO 89/06700
- Miyoshi *et al.*, *Proc. Natl. Acad. Sci. USA* 94:10319-10323.
- Mizukami *et al.*, *Virology*, 217:124-130, 1996.
- 10 Mulligan *et al.*, *Proc. Nat'l Acad. Sci. USA*, 78: 2072, 1981.
- Mulligan, "The basic science of gene therapy," *Science*, 260:926-932, 1993.
- Myers, EP 0273085
- Naldini *et al.*, *Science* 272:263-267.
- Nicolas and Rubenstein, "Retroviral vectors," In: *Vectors: A survey of molecular cloning vectors and their uses*, Rodriguez and Denhardt (eds.), Stoneham: Butterworth, pp. 493-513, 1988.
- 15 Nicolas and Rubenstein, In: *Vectors: A survey of molecular cloning vectors and their uses*, Rodriguez and Denhardt (eds.), Stoneham: Butterworth, pp. 493-513, 1988.
- Nicolau and Sene, "Liposome-mediated DNA transfer in eukaryotic cells," *Biochim. Biophys. Acta*, 721:185-190, 1982.
- 20 Nicolau *et al.*, "Liposomes as carriers for *in vivo* gene transfer and expression," *Methods Enzymol.*, 149:157-176, 1987.
- O'Hare *et al.*, *Proc. Nat'l Acad. Sci. USA*, 78: 1527, 1981.
- Ohara *et al.*, *Proc. Nat'l Acad. Sci. USA*, 86: 5673-5677, 1989.
- 25 Olsen, J. C., L. G. Johnson, J. M. Stutts, B. Sarkadi, J. R. Yankaskas, R. Swanstrom, and R. C. Boucher. 1992. Correction of the apical membrane chloride permeability defect in polarized cystic fibrosis airway epithelia following retroviral-mediated gene transfer. *Hum. Gene Ther.* 3:253-266.
- Olsen, Johnson, Wong-Sun, Moore, Swanstrom, and Boucher, "Retrovirus-mediated gene transfer to cystic fibrosis airway epithelial cells: effect of selectable marker sequences on long-term expression," *Nucleic Acids Res.*, 21(3):663-669, 1993.
- 30 Ostrove *et al.*, *Virology*, 113:532-533, 1981.

- Paskind *et al.*, "Dependence of moloney murine leukemia virus production on cell growth," *Virology*, 67:242-248, 1975.
- Paskind *et al.*, *Virology*, 67:242-248, 1975.
- Pelletier and Sonenberg, *Nature*, 334:320-325, 1988.
- 5 Perales *et al.*, "Gene transfer *in vivo*: Sustained expression and regulation of genes introduced into the liver by receptor-targeted uptake," *Proc. Natl. Acad. Sci.* 91:4086-4090, 1994.
- Pignon *et al.*, *Hum. Mutat.*, 3: 126-132, 1994.
- Poeschla, E. M., F. W-Staal, and D. L. Looney. 1998. Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors. *Nature Med.* 4:354-
10 357.
- Ponnazhagan *et al.*, *Hum. Gene Ther.*, 8:275-284, 1997a.
- Ponnazhagan *et al.*, *J. Gen. Virol.*, 77:1111-1122, 1996.
- Post *et al.*, *Cell*, 24:555-565, 1981.
- Potter *et al.*, "Enhancer-dependent expression of human k immunoglobulin genes introduced
15 into mouse pre-B lymphocytes by electroporation," *Proc. Nat. Acad. Sci. USA*, 81:7161-7165, 1984.
- Racher *et al.*, *Biotechnology Techniques*, 9:169-174, 1995.
- Ragot *et al.*, "Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of *mdx* mice," *Nature*, 361:647-650, 1993.
- 20 Renan, "Cancer genes: Current status, future prospects and applications in radiotherapy/oncology," *Radiother. Oncol.*, 19:197-218, 1990.
- Renan, *Radiother. Oncol.*, 19:197-218, 1990.
- Rich *et al.*, "Development and analysis of recombinant adenoviruses for gene therapy of cystic fibrosis," *Hum. Gene Ther.*, 4:461-476, 1993.
- 25 Ridgeway, "Mammalian expression vectors," In: Rodriguez RL, Denhardt DT, ed. *Vectors: A survey of molecular cloning vectors and their uses*. Stoneham: Butterworth, pp. 467-492, 1988.
- Rippe *et al.*, "DNA-mediated gene transfer into adult rat hepatocytes in primary culture," *Mol. Cell Biol.*, 10:689-695, 1990.
- 30 Roizman and Sears, In *Fields' Virology*, 3rd Edition, eds. Fields *et al.* (Raven Press, New York, N.Y.), pp. 2231-2295, 1995.

- Rosenfeld *et al.*, "In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium," *Cell*, 68:143-155, 1992.
- Roux *et al.*, "A versatile and potentially general approach to the targeting of specific cell types by retroviruses: Application to the infection of human cells by means of major histocompatibility complex class I and class II antigens by mouse ecotropic murine leukemia virus-derived viruses," *Proc. Natl Acad. Sci. USA*, 86:9079-9083, 1989.
- Sambrook *et al.*, *Molecular cloning: A laboratory manual*, 2d Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.
- Samulski *et al.*, *EMBO J.*, 10:3941-3950, 1991.
- Srivastava *et al.*, *J. Virol.*, 45:555-564, 1983.
- Stinchcomb *et al.*, *Nature*, 282: 39, 1979.
- Stratford-Perricaudet and Perricaudet, "Gene transfer into animals: the promise of adenovirus," p. 51-61, In: *HUMAN GENE TRANSFER*, Cohen-Haguenauer and Boiron (eds.), Editions John Libbey Eurotext, France, 1991.
- Stratford-Perricaudet *et al.*, "Evaluation of the transfer and expression in mice of an enzyme-encoding gene using a human adenovirus vector," *Hum. Gene. Ther.*, 1:241-256, 1990.
- Summers *et al.*, "A manual of methods for baculovirus vectors and insect cell culture procedures," Texas Agriculture Experimental Station.
- Szybalska *et al.*, *Proc. Nat'l Acad. Sci. USA*, 48:2026, 1962.
- Temin, "Retrovirus vectors for gene transfer: Efficient integration into and expression of exogenous DNA in vertebrate cell genome," In: *Gene Transfer*, Kucherlapati (ed.), New York, Plenum Press, pp. 149-188, 1986.
- Temin, In: *Gene Transfer*, Kucherlapati (ed.), New York: Plenum Press, pp. 149-188, 1986.
- Top *et al.*, "Immunization with live types 7 and 4 adenovirus vaccines. II. Antibody response and protective effect against acute respiratory disease due to adenovirus type 7," *J. Infect. Dis.*, 124:155-160, 1971.
- Tschemper *et al.*, *Gene*, 10: 157, 1980.
- Tur-Kaspa *et al.*, "Use of electroporation to introduce biologically active foreign genes into primary rat hepatocytes," *Mol. Cell Biol.*, 6:716-718, 1986.
- U.S. Patent No. 4,683,195
- U.S. Patent No. 4,683,202

U.S. Patent No. 4,800,159

Varmus *et al.*, "Retroviruses as mutagens: Insertion and excision of a nontransforming provirus alter the expression of a resident transforming provirus," *Cell*, 25:23-36, 1981.

Wagner *et al.*, *Proc. Natl. Acad. Sci.* 87(9):3410-3414, 1990.

5 Wagner *et al.*, *Science*, 260:1510-1513, 1993.

Walker *et al.*, *Proc. Nat'l Acad. Sci. USA* 89:392-396 1992.

Wigler *et al.*, *Cell*, 11: 223, 1977.

Wigler *et al.*, *Proc. Nat'l Acad. Sci. USA*, 77: 3567, 1980.

10 Wong *et al.*, "Appearance of β -lactamase activity in animal cells upon liposome mediated gene transfer," *Gene*, 10:87-94, 1980.

Wu and Wu, "Evidence for targeted gene delivery to HepG2 hepatoma cells *in vitro*," *Biochem.*, 27:887-892, 1988.

Wu and Wu, "Receptor-mediated *in vitro* gene transfections by a soluble DNA carrier system," *J. Biol. Chem.*, 262:4429-4432, 1987.

15 Wu and Wu, *Adv. Drug Delivery Rev.*, 12:159-167, 1993.

Wu *et al.*, *Genomics*, 4:560, 1989.

Yang *et al.*, "In vivo and *in vitro* gene transfer to mammalian somatic cells by particle bombardment," *Proc. Natl. Acad. Sci USA*, 87:9568-9572, 1990.

20 Zelenin *et al.*, "High-velocity mechanical DNA transfer of the chloramphenicol acetyltransferase gene into rodent liver, kidney and mammary gland cells in organ explants and *in vivo*," *FEBS Lett.*, 280:94-96, 1991.

CLAIMS:

1. A method for the synthesis of a replication-competent, double-stranded polynucleotide, wherein said polynucleotide comprises an origin of replication, a first coding region and a first regulatory element directing the expression of said first coding region, comprising the steps of:
- 5
- (a) generating a first set of oligonucleotides corresponding to the entire plus strand of said double-stranded polynucleotide;
- (b) generating a second set of oligonucleotides corresponding to the entire minus strand of said double-stranded polynucleotide; and
- 10
- (c) annealing said first and said second set of oligonucleotides;
- wherein each of said oligonucleotides of said second set of oligonucleotides overlaps with and hybridizes to two complementary oligonucleotides of said first set of oligonucleotides, except that two oligonucleotides at a 5' or 3' end of said double-stranded polynucleotide will hybridize with only one complementary oligonucleotide.
- 15
2. The method of claim 1, further comprising the step of treating said annealed oligonucleotides with a ligating enzyme to generate continuous strands of said double-stranded polynucleotide.
- 20
3. The method of claim 1, further comprising the step of amplifying said double-stranded polynucleotide.
- 25
4. The method of claim 1, wherein said double-stranded polynucleotide comprises 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 5000, 10×10^3 , 20×10^3 , 30×10^3 , 40×10^3 , 50×10^3 , 60×10^3 , 70×10^3 , 80×10^3 , 90×10^3 , 1×10^4 , 1×10^5 , 1×10^6 , 1×10^7 , 1×10^8 , 1×10^9 or 1×10^{10} base pairs in length.
- 30
5. The method of claim 1, wherein said first regulatory element is a promoter.

6. The method of claim 5, wherein said double-stranded polynucleotide comprises a second regulatory element, said second regulatory element being a polyadenylation signal.
- 5 7. The method of claim 1, wherein said double-stranded polynucleotide comprises a plurality of coding regions and a plurality of regulatory elements.
8. The method of claim 7, wherein said coding regions encode products that comprise a biochemical pathway.
- 10 9. The method of claim 8, wherein said biochemical pathway is glycolysis.
10. The method of claim 9, wherein said coding regions encode enzymes selected from the group consisting of hexokinase, phosphohexose isomerase, phosphofructokinase-1, aldolase, triose-phosphate isomerase, glyceraldehyde-3-phosphate dehydrogenase, phosphoglycerate kinase, phosphoglycerate mutase, enolase and pyruvate kinase.
- 15 11. The method of claim 8, wherein said biochemical pathway is lipid synthesis.
12. The method claim 7, wherein said biochemical pathway is cofactor synthesis.
- 20 13. The method of claim 13, wherein said pathway involves lipoic acid.
14. The method of claim 13, wherein said biochemical pathway is riboflavin synthesis.
- 25 15. The method of claim 7, wherein said biochemical pathway is nucleotide synthesis.
16. The method of claim 15, wherein said nucleotide is a purine.
- 30 17. The method of claim 15, wherein said nucleotide is a pyrimidine.

18. The method of claim 7, wherein said coding regions encode enzymes involved in a cellular process selected from the group consisting of cell division, chaperone, detoxification, peptide secretion, energy metabolism, regulatory function, DNA replication, transcription, RNA processing and tRNA modification.
- 5
19. The method of claim 18, wherein said energy metabolism is oxidative phosphorylation.
20. The method of claim 1, wherein said double-stranded polynucleotide is a DNA.
- 10
21. The method of claim 1, wherein said double-stranded polynucleotide is an RNA.
22. The method of claim 1, wherein said double-stranded polynucleotide is an expression construct.
- 15
23. The method of claim 22, wherein said expression construct is a bacterial expression construct.
24. The method of claim 22, wherein said expression construct is a mammalian expression construct.
- 20
25. The method of claim 17, wherein said expression construct is a viral expression construct.
26. The method of claim 1, wherein said double-stranded polynucleotide comprises a genome selected from the group consisting of bacterial genome, yeast genome, viral genome, mammalian genome, amphibian genome and avian genome.
- 25
27. The method of claim 1, wherein said overlap between the oligonucleotides of said first and said second set of oligonucleotides is between about 5 base pairs and about 75 base pairs.
- 30

28. The method of claim 1, wherein said overlap is about 10 base pairs, about 15 base pairs, about 20 base pairs, about 25 base pairs, about 30 base pairs, about 35 base pairs, about 40 base pairs, about 45 base pairs, about 50 base pairs, about 55 base pairs, about 60 base pairs, about 65 base pairs, or about 70 base pairs.

5

29. The method of claim 5, wherein said promoter is selected from the group consisting of CMV IE, SV40 IE, RSV, β -actin, tetracycline regulatable and ecdysone regulatable.

30. The method of claim 26, wherein said genome is a viral genome.

10

31. The method of claim 30, wherein said viral genome is selected from the group consisting of retrovirus, adenovirus, vaccinia virus, herpesvirus and adeno-associated virus.

15

32. The method of claim 1, wherein said double-stranded polynucleotide is a chromosome.

33. A method of producing a viral particle comprising the steps of:

20

(a) providing a host cell;

(b) transforming said host cell with an artificial viral genome prepared by:

25

(i) generating a first set of oligonucleotides corresponding to the entire plus strand of said viral genome;

(ii) generating a second set of oligonucleotides corresponding to the entire minus strand of said viral genome; and

(iii) annealing said first and said second set of oligonucleotides;

30

wherein each of said oligonucleotides of said second set of oligonucleotides overlaps with and hybridizes to two complementary oligonucleotides of said first set of oligonucleotides, except that two oligonucleotides at a 5' or 3' end of said viral genome will hybridize with only one complementary oligonucleotide; and

(c) culturing said transformed host cell under conditions such that said viral particle is expressed.

34. The method of claim 33, wherein said viral genome is selected from the group consisting of retrovirus, adenovirus, vaccinia virus, herpesvirus and adeno-associated virus.

35. A method of producing an artificial genome, wherein said chromosome comprises all coding regions and regulatory elements found in a corresponding natural chromosome, comprising the steps of:

- (a) generating a first set of oligonucleotides corresponding to the entire plus strand of said chromosome;
- (b) generating a second set of oligonucleotides corresponding to the entire minus strand of said chromosome; and
- (c) annealing said first and said second set of oligonucleotides;

wherein each of said oligonucleotides of said second set of oligonucleotides overlaps with and hybridizes to two complementary oligonucleotides of said first set of oligonucleotides, except that two oligonucleotides at a 5' or 3' end of said chromosome will hybridize with only one complementary oligonucleotide.

36. The method of claim 35, wherein said corresponding natural chromosome is a human mitochondrial genome.

37. The method of claim 35, wherein said corresponding natural chromosome is a chloroplast genome.

38. A method of producing an artificial genetic system, wherein said system comprises all coding regions and regulatory elements found in a corresponding natural biochemical pathway, comprising the steps of:

- 5 (a) generating a first set of oligonucleotides corresponding to the entire plus strand of said chromosome;
- (b) generating a second set of oligonucleotides corresponding to the entire minus strand of said chromosome; and
- (c) annealing said first and said second set of oligonucleotides;

10 wherein each of said oligonucleotides of said second set of oligonucleotides overlaps with and hybridizes to two complementary oligonucleotides of said first set of oligonucleotides; except that two oligonucleotides at a 5' or 3' end of said chromosome will hybridize with only one complementary oligonucleotide

wherein expression of said biochemical pathway coding regions results in the expression of a group of enzymes that serially metabolize a compound.

- 15 39. The method of claim 38, wherein said biochemical pathway comprises the activities required for glycolysis.
40. The method of claim 38, wherein said biochemical pathway comprises the enzymes required for electron transport.
- 20 41. The method of claim 38, wherein said biochemical pathway comprises the enzyme activities required for photosynthesis.

1/21

DNA SEQUENCE INFORMATION

- Step 1. Determine/design DNA sequence of the genome
- ↓
- Step 2. Synthesize and assemble the genomic DNA
- ↓
- Step 3. Introduce the DNA into an enucleated pleuripotent host cell.
- ↓
- Step 4. Introduce the host cell into a foster mother animal

SYNTHETIC ORGANISM

FIG. 1

2/21

1. Design genome, containing prokaryotic origin of replication and drug selection vector.
↓
2. SynGen 2.0, breaks down genome into component overlapping oligonucleotides, programs oligonucleotide synthesizer.
↓
3. Chemical synthesis of component oligonucleotide using MERMADE high throughput synthesizer.
↓
4. Combinatoric assembly of component oligonucleotides using robotic processing.
↓
5. Transformation into component bacteria.

FIG. 2

3/21




FIG. 3

4/21

10 20 30 40 50 60 70 80 90 100
 aagcttacctcgatttgaggacgttacaagattactgttaaggagcglagattaaaaaatgaaattgaaaaatgaattattagaattggcttaataaac
 agaatacccaaaaaggaaatagagtatgaagtttgaaatatttggtttttcgtatcaaccaccagggtgaaactcataagctaagtaaatggatcgctttgtt
 luxA --- >
 cggcttggtatcgctcagaagagtagggttgatacatatttgacccttagaacatcattttacagagtttggcttacgggaaattatttgttgctgc
 ggctaacctgttaggaagaactaaaacattaaatgttgacctatggttgacctatggttattccgacagcacaccagttcgacagttagaagacgtttttattat
 ttgatcaaatgtcgaaaggctgttttaatttgaaaccgttcgaggctataccataaagattttcgaglatttgggttgatatggaagagtcctcgag
 caattactcaaaaatttctaccagatgataatggaaagcttacagacaggaaccattagctctgatatgattacatttcaatttccctaaaggttgatgtata
 tcccaagtgactcaaaaaatgtaccaacctgtatgactgctgagtcgcaagtagcacagaatggctagcaatacaagggtaccaatggttcttagt
 tggattattgggtactaatgaaaaaaagcacagatggaaactctataatgaaattgcgacagaaatattggtcatgataatactaaaaatagatcattgtatga
 cttatatttgttctgtgatgatgcacaaaaggcgcaagatgtttgtcgggagtcttgaaaaatttggtagctcatatgtataatcgaccaatat
 ctttaatatgtagcaatcaaacctggtgttatgatatacaaaaggtcaatggctgatttgttttacaggacatacaaaacaccaatcgacgtgttgat
 tatagcaatggtattaacctgtaggcactcctgagcagtgatttgaatcatcaacgtgatatgtagcaacgggtattacaacattacatgcggat
 ttgaagctaattggaactgaagatgaaataattgcttccatgcgacgctttatgacacaagtcgctccttctttaaagaacctaataaatacttattt
 gatactagagataataaaggacaagttatgaaatttggattatttttctaaactttcagaaagatggaaataaacatctgaaagaaacgttggaataatatgg
 luxB --- >
 taaagactgtcacgttaattgattcaactaaatatcatctttaaactgcctttgttaatgaacatcacttttcaaaaaatgggtattgttggagcacctat
 taccgcagctggttttttatagggttaacaaataaattacataattggttcattaaatcaagtaattaccaccatcacctgtacgtgtagcagaagaa
 gccagttattagatcaaatgtcagaggacgcttcattcttggttttagtgactgcgaaagtgtttcgaaatggaatttttagacgtcatatctcat
 caaggcaacaacaatttgaagcatgctatgaaataatgaatgacgcattaaactacaggttattgtcatcccccaaacgactttttatgattttccaaaggt
 ttcaattaatccacactgttacagtggagaatggacctaaagcaatattgtatccgtacatcaaaagaagtcgtcatgtgggcagcgaagaaaggcactgcct
 taacatttaagtggaggataatttagaaaccaaaagacgctatgcaattctataataaaacagcacaacaatatgggtattgatatctcggtgttg
 atcatcaattaaactgtaattgcgaacttaaatgctgtagaagtagcgtcaagaagaagtgaagaaactactaaaagactatatacactgaaacttacc
 tcaaatggacagagatgaaaaaataactgcattattgaagagaaatgcagttgggtctcatgatgactattatgaatcgacaaaaattagcagtggaaaaa
 acaggttctaaaaatatttattatcccttgaatcaatgtccgatattaaagatgtaaaagataattattgatattgtgaacccaaaaaatcgaaatgaatt
 taccataataaaaaattaaaggcaatttctataattagattgccttttggggatcctctagaaatatttttatctgtatataaagatgagaattcactggccg
 pUC 19 --- >

FIG. 4A

5/21

tcgtttacaacgtcgtgactgggaaaccctggcgttaccacactaatcgccctgcagcacatcccccttcgccagctggcgtaataagcgaagaggc
 ccgacccgatcgcccttcccaacagttgcgcagcctgaatggcgaatggcgccctgatcggtattttctccttacgcattctgtcggtatttcacaccgc
 atatgtgactctcagfacaatctgctctgatgccgcatagttaaagccagcccgacacccgccaacacccgctgacgcgcctgacgggcttgctgc
 tcccgcatccgcttacagacaagctgtgaccgtctccggagctgcatgtgtcagaggttttcacgtcatcacgaaacgcgcgagacgaaagggcct
 cgtgataccgctattttataggttaattgtcatgataataatggtttcttagacgtcaggtggcacttttcgggaaatgtgcggaacccctatttgt
 ttattttctaaaaagcttcacgctgccgcaagcactcaggcgcaaggctgctaaaggaagcggaaacagtagaaagccagtcgcgcagaaacggtgct
 gaccccgatgaatgtcagctactgggctatctggacaagggaacgcaagcgcaagagaaagcaggtagctgcagtgggcttacatggcgatagct
 agactggcggttttatggacagcaagcaaccggaattgccagctggggcgccctctgtaaggttgggaagccctgcaaaagtaaacctggatggcttcc
 ttgccccaaggatctgatggcgagggtatcaagatctgataagagacaggatgaggatcggttcgcatgattgaacaagatggattgcacgcagggtt
 kan/neo phosphotransferase ---
 ctccggccgcttgggtggagaggctattcggctatgactggggcacaacagacaatcggctgctctgtatgccgcgctgttccggctgcagcgaggggcg
 -- >
 cccggttcttttgtcaagaccgacctgtccggtgccctgaatgaactgcaggacgagcgcggtatcgtggctggccacgacggcggttcccttgc
 gcagctgtgctcgacgttgtcactgaagcgggaaggactggctgctattggcggaagtgcggggcaggatctcctgtcatctcaccttgctcctgccg
 agaaagtatccatcatggctgatgcaatgcggcggtgcatacgcttgatccggctacctgcccattcgaccaccaagcgaacatcgcatcgagcgagc
 acgtactcggatggaagccggtcttgtcgatcaggatgatctggacgaagagcatcaggggctcgccagccgaactgttcgccaggctcaaggcgcg
 atgcccgacggcgaggatctcgtcgtgaccatggcgatgcctgcttgccgaatatcatggttggaataatggcgcttcttggtattcatcgactgtggcc
 gctgggtgtggcgaccgctatcaggacatagcgttggctaccgctgatatgtctgaagagcttggcgcggaatgggctgaccgcttccctcgtgcttta
 cggatcgccgtcccgattcgacgcgcatcgcttctatcgcttcttgacgagttcttctgagcgggactctggggttcgaaatgaccgaccgaagcga
 cgcccaacctgccatcacgagatttcgattccaccgcgcttctatgaaaggttgggcttcggaatcggtttccgggacgcccggctggatgatcctcca
 pUC19 ---- >

FIG. 4B

6/21

gcgcgggatctcatgctggagttcttcgcccaccccgggcatgacccaaaatcccttaacgtgagttttcgttccactgagcgtcagaccccgtagaaaa
gatcaaaggatctcttgagatcctttttctcgcgtaattctgctgcttgcaaacaaaaaacaccgctaccagcgggtgttgttgcgggatcaa
gagctaccaactcttttccgaaggtaactggcttcagcagagcgagataccaaatactgtccttctagttagccgtagttaggccaccacttcaaga
actctgtagcaccgcctacataacctcgctctgctaatcctgttaccagtggctgctgccagtggcgataagtcggtcttaccgggttggactcaagacg
atagttaccggataaaggcgacgggtcgggctgaacggggggttcgtgcacacagcccagcttgagcgaaacgacctacaccgaactgagataacctacag
cgtgagctatgagaaagcgccacgcttcccgaaggagaaaggcgacaggtatccggtaagcggcagggtcggaaacaggaagcgacgagggagcttc
cagggggaacggcctgggtatcttatagtcctgtcgggttcgccacctctgacttgagcgtcgatttttctgtatgctcgtcaggggggaggagcctatg

FIG. 4C

7/21

oligoF01, AAGCTTACCTCGATTTGAGGACGTTACAAGTATTACTGTTAAGGAGCGTA
oligoF02, GATTAATAAATGAAATTGAAATGAATTATTAGAATTGGCTTAAATAAAC
oligoF03, AGAATCACCAAAAAGGAATAGAGTATGAAGTTTGGAAATATTTGTTTTTC
oligoF04, GTATCAACCACCAGGTGAACTCATAAGCTAAGTAATGGATCGCTTTGTT
oligoF05, CGGCTTGGTATCGCCTCAGAAGAGTAGGGTTTGATACATATTGGACCTTA
oligoF06, GAACATCATTTTACAGAGTTTGGTCTTACGGGAAATTTATTTGTTGCTGC
oligoF07, GGCTAACCTGTTAGGAAGAACTAAAACATTAAATGTTGGCACTATGGGGG
oligoF08, TTGTTATTCCGACAGCACACCCAGTTCGACAGTTAGAAGACGTTTTATTA
oligoF09, TTAGATCAAATGTCGAAAGGTCGTTTTAATTTTGAACCGTTCGAGGGCT
oligoF10, ATACCATAAAGATTTTCGAGTATTTGGTGTGATATGGAAGAGTCTCGAG
oligoF11, CAATTACTCAAAATTTCTACCAGATGATAATGGAAAGCTTACAGACAGGA
oligoF12, ACCATTAGCTCTGATAGTGATTACATTCAATTTCTAAGGTTGATGTATA
oligoF13, TCCCAAAGTGTACTCAAAAAATGTACCAACCTGTATGACTGCTGAGTCCG
oligoF14, CAAGTACGACAGAATGGCTAGCAATACAAGGGCTACCAATGGTTCTTAGT
oligoF15, TGGATTATTGGTACTAATGAAAAAAGCACAGATGGAAGTCTATAATGA
oligoF16, AATTGCGACAGAATATGGTCATGATATATCTAAAATAGATCATTGTATGA
oligoF17, CTTATATTTGTTCTGTTGATGATGATGCACAAAAGGCGCAAGATGTTTGT
oligoF18, CGGGAGTTTCTGAAAAATTGGTATGACTCATATGTAAATGCGACCAATAT
oligoF19, CTTTAATGATAGCAATCAAACCTCGTGGTTATGATTATCATAAAGGTCAAT
oligoF20, GGCGTGATTTTGTGTTTACAAGGACATACAAACACCAATCGACGTGTTGAT
oligoF21, TATAGCAATGGTATTAACCCTGTAGGCACTCCTGAGCAGTGTATTGAAAT
oligoF22, CATTCAACGTGATATTGATGCAACGGGTATTACAAACATTACATGCGGAT
oligoF23, TTGAAGCTAATGGAAGTGAAGATGAAATAATTGCTTCCATGCGACGCTTT
oligoF24, ATGACACAAGTCGCTCCTTTCTTAAAAGAACCTAAATAAATTACTTATTT
oligoF25, GATACTAGAGATAATAAGGAACAAGTTATGAAATTTGGATTATTTTTTCT
oligoF26, AAACTTTCAGAAAGATGGAATAACATCTGAAGAAACGTTGGATAATATGG
oligoF27, TAAAGACTGTCACGTTAATTGATTCAACTAAATATCATTTTAATACTGCC
oligoF28, TTTGTTAATGAACATCACTTTTCAAAAAATGGTATTGTTGGAGCACCTAT
oligoF29, TACCGCAGCTGGTTTTTTTATTAGGGTTAACAAATAAATTACATATTGGTT

FIG. 5A

8/21

oligoF30, CATTAAATCAAGTAATTACCACCCATCACCTGTACGTGTAGCAGAAGAA
oligoF31, GCCAGTTTATTAGATCAAATGTCAGAGGGACGCTTCATTCTTGGTTTTAG
oligoF32, TGA CTGCGAAAGTGATTTGAAATGGAATTTTTTAGACGTCATATCTCATV
oligoF33, CAAGGCAACAACAATTTGAAGCATGCTATGAAATAATTAATGACGCATTA
oligoF34, ACTACAGGTTATTGT CATCCCCAAAACGACTTTTATGATTTTCCAAAGGT
oligoF35, TTCAATTAATCCACACTGTTACAGTGAGAATGGACCTAAGCAATATGTAT
oligoF36, CCGCTACATCAAAAGAAGTCGT CATGTGGGCAGCGAAAAAGGCACTGCCT
oligoF37, TTAACATTTAAGTGGGAGGATAATTTAGAAACCAAAGAACGCTATGCAAT
oligoF38, TCTATATAATAAAACAGCACAACAATATGGTATTGATATTTCCGATGTTG
oligoF39, ATCATCAATTA ACTGTAATTGCGAACTTAAATGCTGATAGAAGTACGGCT
oligoF40, CAAGAAGAAGTGAGAGAATACTTAAAAGACTATATCACTGAAACTTACCC
oligoF41, TCAAATGGACAGAGATGAAAAAATTA ACTGCATTATTGAAGAGAATGCAG
oligoF42, TTGGGTCTCATGATGACTATTATGAATCGACAAAATTAGCAGTGGAAAAA
oligoF43, ACAGGGTCTAAAAATATTTTATTATCCTTTGAATCAATGTCCGATATTAA
oligoF44, AGATGTAAAAGATATTATTGATATGTTGAACCAAAAAATCGAAATGAATT
oligoF45, TACCATAATAAAATTAAGGCAATTTCTATATTAGATTGCCTTTTTGGGG
oligoF46, ATCCTCTAGAAATATTTTATCTGATTAATAAGATGAGAATTC ACTGGCCG
oligoF47, TCGTTTTACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCA ACTTAAT
oligoF48, CGCCTTGCAGCACATCCCCCTTCGCCAGCTGGCGTAATAGCGAAGAGGC
oligoF49, CCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGC
oligoF50, GCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCGGTATTTACACCGC
oligoF51, ATATGGTGCACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCA
oligoF52, GCCCCGACACCCGCCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGC
oligoF53, TCCCGGCATCCGCTTACAGACAAGCTGTGACCGTCTCCGGGAGCTGCATG
oligoF54, TGTCAGAGGTTTTACCGTCATCACCGAAACGCGCGAGACGAAAGGGCCT
oligoF55, CGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTT
oligoF56, AGACGTCAGGTGGCACTTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGT
oligoF57, TTATTTTTCTAAAAAGCTTCACGCTGCCGCAAGCACTCAGGGCGCAAGGG
oligoF58, CTGCTAAAGGAAGCGGAACACGTAGAAAGCCAGTCCGCAGAAACGGTGCT
oligoF59, GACCCCGGATGAATGTCAGCTACTGGGCTATCTGGACAAGGGAAAACGCA
oligoF60, AGCGCAAAGAGAAAGCAGGTAGCTTGCAGTGGGCTTACATGGCGATAGCT
oligoF61, AGACTGGGCGGTTTTATGGACAGCAAGCGAACC GGAATTGCCAGCTGGGG

FIG. 5B

SUBSTITUTE SHEET (RULE 26)

9/21

oligoF63. TTGCCGCCAAGGATCTGATGGCGCAGGGGATCAAGATCTGATCAAGAGAC
oligoF64. AGGATGAGGATCGTTTTCGCATGATTGAACAAGATGGATTGCACGCAGGTT
oligoF65. CTCCGGCCGCTTGGGTGGAGAGGCTATTCCGGCTATGACTGGGCACAACAG
oligoF66. ACAATCGGCTGCTCTGATGCCGCCGTGTTCCGGCTGTCAGCGCAGGGGGCG
oligoF67. CCCGGTTCTTTTTGTCAAGACCGACCTGTCCGGTGCCCTGAATGAACTGC
oligoF68. AGGACGAGGCAGCGCGGCTATCGTGGCTGGCCACGACGGGCGTTCCTTGC
oligoF69. GCAGCTGTGCTCGACGTTGTCACTGAAGCGGGAAGGGACTGGCTGCTATT
oligoF70. GGGCGAAGTGCCGGGGCAGGATCTCCTGTCATCTCACCTTGCTCCTGCCG
oligoF71. AGAAAGTATCCATCATGGCTGATGCAATGCGGCGGCTGCATACGCTTGAT
oligoF72. CCGGCTACCTGCCCATTGACCACCAAGCGAAACATCGCATCGAGCGAGC
oligoF73. ACGTACTCGGATGGAAGCCGGTCTTGTGATCAGGATGATCTGGACGAAG
oligoF74. AGCATCAGGGGCTCGCGCCAGCCGAAGTTCGCCAGGCTCAAGGCGCGC
oligoF75. ATGCCCGACGGCGAGGATCTCGTCGTGACCCATGGCGATGCCTGCTTGCC
oligoF76. GAATATCATGGTGGAAAATGGCCGCTTTTCTGGATTCATCGACTGTGGCC
oligoF77. GGCTGGGTGTGGCGGACCGCTATCAGGACATAGCGTTGGCTACCCGTGAT
oligoF78. ATTGCTGAAGAGCTTGGCGGCGAATGGGCTGACCGCTTCCTCGTGCTTTA
oligoF79. CGGTATCGCCGCTCCCGATTGCGAGCGCATCGCCTTCTATCGCCTTCTTG
oligoF80. ACGAGTTCTTCTGAGCGGGACTCTGGGGTTCGAAATGACCGACCAAGCGA
oligoF81. CGCCCAACCTGCCATCACGAGATTTGATTCCACCGCCGCTTCTATGAA
oligoF82. AGGTTGGGCTTCGGAATCGTTTTCCGGGACGCCGGCTGGATGATCCTCCA
oligoF83. GCGCGGGGATCTCATGCTGGAGTTCTTCGCCACCCCGGGCATGACCAAA
oligoF84. ATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAA
oligoF85. GATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCT
oligoF86. TGCAAACAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAA
oligoF87. GAGCTACCAACTCTTTTTCCGAAGGTAAGTGGCTTCAGCAGAGCGCAGAT
oligoF88. ACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGA
oligoF89. ACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTG
oligoF90. GCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACG
oligoF91. ATAGTTACCGGATAAGGCGCAGCGGTGGGGCTGAACGGGGGTTCTGTGCA
oligoF92. CACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAG
oligoF93. CGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAG
oligoF94. GTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTC

FIG. 5C

10/21

oligoF96, TGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATG
oligoR01, CATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACT
oligoR02, ATAAAGATACCAGGCGTTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTG
oligoR03, TTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGA
oligoR04, AGCGTGGCGCTTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTA
oligoR05, GGTCGTTGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCG
oligoR06, ACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGA
oligoR07, CACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGC
oligoR08, GAGGTATGTAGGCGGTGCTACAGAGTTCCTTGAAGTGGTGGCCTAACTACG
oligoR09, GCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTT
oligoR10, ACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGC
oligoR11, TGGTAGCGGTGGTTTTTTTGTGTTGCAAGCAGCAGATTACGCGCAGAAAAA
oligoR12, AAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAG
oligoR13, TGGAACGAAAACCTCACGTTAAGGGATTTTGGTCATGCCCGGGGTGGGCGA
oligoR14, AGAACTCCAGCATGAGATCCCCGCGCTGGAGGATCATCCAGCCGGCGTCC
oligoR15, CGGAAAACGATTCCGAAGCCCAACCTTTCATAGAAGGCGGCGGTGGAATC
oligoR16, GAAATCTCGTGATGGCAGGTTGGGCGTCGCTTGGTCGGTCATTTGAAACC
oligoR17, CCAGAGTCCCGCTCAGAAGAACTCGTCAAGAAGGCGATAGAAGGCGATGC
oligoR18, GCTGCGAATCGGGAGCGGCGATACCGTAAAGCACGAGGAAGCGGTGAGCC
oligoR19, CATTCGCCGCCAAGCTCTTCAGCAATATCACGGGTAGCCAACGCTATGTC
oligoR20, CTGATAGCGGTCCGCCACACCCAGCCGGCCACAGTCGATGAATCCAGAAA
oligoR21, AGCGGCCATTTTCCACCATGATATTCGGCAAGCAGGCATCGCCATGGGTCT
oligoR22, ACGACGAGATCCTCGCCGTCGGGCATGCGCGCCTTGAGCCTGGCGAACAG
oligoR23, TTCGGCTGGCGCGAGCCCCTGATGCTCTTCGTCCAGATCATCCTGATCGA
oligoR24, CAAGACCGGCTTCCATCCGAGTACGTGCTCGCTCGATGCGATGTTTCGCT
oligoR25, TGGTGGTCGAATGGGCAGGTAGCCGGATCAAGCGTATGCAGCCGCCGCAT
oligoR26, TGCATCAGCCATGATGGATACTTTCTCGGCAGGAGCAAGGTGAGATGACA
oligoR27, GGAGATCCTGCCCCGGCACTTCGCCCAATAGCAGCCAGTCCCTTCCCGCT
oligoR28, TCAGTGACAACGTCGAGCACAGCTGCGCAAGGAACGCCCGTCTGTGGCCAG
oligoR29, CCACGATAGCCGCGCTGCCTCGTCCTGCAGTTCATTGAGGGCACCCGACA
oligoR30, GGTGCGTCTTGACAAAAAGAACCGGGCGCCCCCTGCGCTGACAGCCGGAAC
oligoR31, ACGGCGGCATCAGAGCAGCCGATTGTCTGTTGTGCCAGTCATAGCCGAA

FIG. 5D

SUBSTITUTE SHEET (RULE 26)

11/21

oligoR33, CAATCATGCGAAACGATCCTCATCCTGTCTCTTGATCAGATCTTGATCCC
oligoR34, CTGCGCCATCAGATCCTTGGCGGCAAGAAAGCCATCCAGTTTACTTTGCA
oligoR35, GGGCTTCCCAACCTTACCAGAGGGCGCCCCAGCTGGCAATTCGGTTTCGC
oligoR36, TTGCTGTCCATAAAACCGCCCCAGTCTAGCTATCGCCATGTAAGCCCACTG
oligoR37, CAAGCTACCTGCTTTCTCTTTGCGCTTGCCTTTTCCCTTGTCCAGATAGC
oligoR38, CCAGTAGCTGACATTCATCCGGGGTCCAGCACCGTTTCTGCGGACTGGCTT
oligoR39, TCTACGTGTTCCGCTTCTTTAGCAGCCCTTGCGCCCTGAGTGCTTGGCG
oligoR40, CAGCGTGAAGCTTTTTAGAAAAATAAACAAATAGGGGTTCGCGGCACATT
oligoR41, TCCCCGAAAAGTGCCACCTGACGTCTAAGAAACCATTATTATCATGACAT
oligoR42, TAACCTATAAAAATAGGCGTATCACGAGGCCCTTTCGTCTCGCGCGTTTC
oligoR43, GGTGATGACGGTGAAAACCTCTGACACATGCAGCTCCCGGAGACGGTCAC
oligoR44, AGCTTGTCTGTAAGCGGATGCCGGGAGCAGACAAGCCCGTCAGGGCGCGT
oligoR45, CAGCGGGTGTTGGCGGGTGTCGGGGCTGGCTTAACCTATGCGGCATCAGAG
oligoR46, CAGATTGTAAGTGCAGAGTGCACCATATGCGGTGTGAAATACCGCACAGATG
oligoR47, CGTAAGGAGAAAATACCGCATCAGGCGCCATTCGCCATTCAGGCTGCGCA
oligoR48, ACTGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCGCTATTACGCCAGCTG
oligoR49, GCGAAAGGGGGATGTGCTGCAAGGCGATTAAGTTGGGTAAACGCCAGGGTT
oligoR50, TTCCCAGTCACGACGTTGTAAAACGACGGCCAGTGAATTCTCATCTTATT
oligoR51, AATCAGATAAAATATTTCTAGAGGATCCCCAAAAGGCAATCTAATATAG
oligoR52, AAATTGCCTTTAATTTTATTATGGTAAATTCATTTTCGATTTTTTGGTTCA
oligoR53, ACATATCAATAATATCTTTTACATCTTTAATATCGGACATTGATTCAAAG
oligoR54, GATAATAAAATATTTTACAGCCCTGTTTTTCCACTGCTAATTTTGTGCA
oligoR55, TTCATAATAGTCATCATGAGACCCAACTGCATTCTCTTCAATAATGCAGT
oligoR56, TAATTTTTTCATCTCTGTCCATTTGAGGGTAAGTTTCAGTGATATAGTCT
oligoR57, TTTAAGTATTCTCTCACTTCTTCTTGAGCCGTAATTCTATCAGCATTTAA
oligoR58, GTTCGCAATTACAGTTAATTGATGATCAACATCCGAAATATCAATACCAT
oligoR59, ATTGTTGTGCTGTTTTATTATATAGAATTGCATAGCGTTCTTTGGTTTCT
oligoR60, AAATTATCCTCCCACTTAAATGTTAAAGGCAGTGCCTTTTTTCGCTGCCCA
oligoR61, CATGACGACTTCTTTTGATGTAGCGGATACATATTGCTTAGGTCCATTCT
oligoR62, CACTGTAACAGTGTGGATTAATTGAAACCTTTGGAAAATCATAAAAGTCG
oligoR63, TTTTGGGGATGACAATAACCTGTAGTTAATGCGTCATTAATTATTTTATA
oligoR64, GCATGCTTCAAATTGTTGTTGCCTTGATGAGATATGACGTCTAAAAAATT

FIG. 5E

SUBSTITUTE SHEET (RULE 26)

12/21

oligoR66, TCTGACATTTGATCTAATAAACTGGCTTCTTCTGCTACACGTACAGGGTG
oligoR67, ATGGGTGGTAATTACTTGATTTAATGAACCAATATGTAATTTATTTGTTA
oligoR68, ACCCTAATAAAAAACCAGCTGCGGTAATAGGTGCTCCAACAATACCATTT
oligoR69, TTTGAAAAGTGATGTTCAATTAACAAAGGCAGTATTAATGATATTTAGT
oligoR70, TGAATCAATTAACGTGACAGTCTTTACCATATTATCCAACGTTTCTTCAG
oligoR71, ATGTTATTCCATCTTTCTGAAAGTTTAGAAAAATAATCCAAATTTCATA
oligoR72, ACTTGTTCCCTTATTATCTCTAGTATCAAATAAGTAATTTATTTAGGTTCT
oligoR73, TTTAAGAAAGGAGCGACTTGTGTCTATAAAGCGTCGCATGGAAGCAATTAT
oligoR74, TTCATCTTCAGTTCCATTAGCTTCAAATCCGCATGTAATGTTTGTAATAC
oligoR75, CCGTTGCATCAATATCACGTTGAATGATTTCAATACACTGCTCAGGAGTG
oligoR76, CCTACAGGGTTAATACCATTGCTATAATCAACACGTCGATTGGTGGTTTGT
oligoR77, ATGTCCTTGTA AAAACAAAATCACGCCATTGACCTTTATGATAATCATAAC
oligoR78, CACGAGTTTGATTGCTATCATTAAAGATATTGGTCGCATTTACATATGAG
oligoR79, TCATACCAATTTTTTCAGAACTCCCGACAAACATCTTGCGCTTTTGTGC
oligoR80, ATCATCATCAACAGAACAAATATAAGTCATACAATGATCTATTTTAGATA
oligoR81, TATCATGACCATATTCTGTGCGAATTTTATTATAGAGTTCCATCTGTGCT
oligoR82, TTTTTTTCATTAGTACCAATAATCCAACTAAGAACCATTGGTAGCCCTTG
oligoR83, TATTGCTAGCCATTCTGTGCTACTTGCGGACTCAGCAGTCATACAGGTTG
oligoR84, GTACATTTTTTGAGTACACTTTGGGATATACATCAACCTTAGGAAATTGA
oligoR85, ATGTAATCACTATCAGAGCTAATGGTTCCTGTCTGTAAGCTTTCCATTAT
oligoR86, CATCTGGTAGAAATTTTGAGTAATTGCTCGAGACTCTTCCATATCAACAC
oligoR87, CAAATACTCGAAAATCTTTATGGTATAGCCCTCGAACGGTTCCAAAATTA
oligoR88, AAACGACCTTTTCGACATTTGATCTAATAATAAAACGTCTTCTAACTGTGC
oligoR89, AACTGGGTGTGCTGTGCGAATAACAACCCCATAGTGCCAACATTTAATG
oligoR90, TTTTAGTTCTTCTTAACAGGTTAGCCGCAGCAACAAATAAATTTCCCGTA
oligoR91, AGACCAAACCTCTGTAAAATGATGTTCTAAGGTCCAATATGTATCAAACCC
oligoR92, TACTCTTCTGAGGCGATACCAAGCCGAACAAAGCGATCCATTACTTAGCT
oligoR93, TATGAGTTTCACCTGGTGGTTGATACGAAAAACAAATATTTCCAACTTC
oligoR94, AACTCTATTCTTTTTTGGTGATTCTGTTTATTTAAGCCAATTCTAATAA
oligoR95, TTCATTTTCAATTTCAATTTTTTAATCTACGCTCCTTAACAGTAATACTTG
oligoR96, TAACGTCCTCAAATCGAGGTAAGCTTCATAGGCTCCGCCCCCTGACGAG

FIG. 5F

13/21

Instruction set for 192 oligos (96 pairs).

1. -F A1 --> -C A1
 -F A2 --> -C A2
 -F A3 --> -C A3
 -F A4 --> -C A4
 repeat with all wells to H12
 -R A1 --> -C A1
 -R A2 --> -C A2
 -R A3 --> -C A3
 -R A4 --> -C A4
 repeat with all wells to H12

All remaining operations on -C plate

2. A1 --> A2
 A3 --> A4
 A5 --> A6
 A7 --> A8
 A9 --> A10
 A11 --> A12
 repeat with each letter
3. A2 --> A4
 A6 --> A8
 A10 --> A12
 repeat with each letter
4. A4 --> A8
 A12 --> B4
 B8 --> B12
 C4 --> C8

FIG. 6A

14/21

- C12 --> D4
D8 --> D12
E4 --> E8
E12 --> F4
F8 --> F12
G4 --> G8
G12 --> H4
H8 --> H12
5. A8 --> B4
B12 --> C8
D4 --> D12
E8 --> F4
F12 --> G8
H4 --> H12
6. B4 --> C8
D12 --> F4
G8 --> H12
7. C8 --> H12
F4 --> H12

FIG. 6B

15/21

```
program Syn_Gene_Formatter (input, output f, g, h);  
  
{Synthetic Gene Formatting Program}  
{This is a draft experimental program designed to break  
down a designer gene or genome}{into oligonucleotides for  
synthesis. The program is for complete synthetic  
designer gene}{construction. The program is based upon  
an original program for formatting DNA sequences}{written  
in 1988 by G. Evans for DNA analysis and formatting}  
{This program is copyright (c) 1997 Glen A. Evans. All  
rights reserved}
```

```
const
```

```
    maxlength = 5000; {maximum length of sequence}  
    searchlength = 10; {maximum length of search string}
```

```
var
```

```
    f: text; {inputfile of sequence}  
    g: text; {output file of sequence}  
    h: text; {output file of sequence}
```

```
{arrays for sequence formatting}
```

```
    dna: array[1..maxlength] of char;  
    rdna: array[1..maxlength] of char;  
    oligo: array[1..100] of char;
```

```
    i, k, seqlength: integer;  
    nucin: char;  
    oligolength, offset: integer;
```

```
    infile, outfile: string
```

FIG. 7A

16/21

```
procedure initialize:
{This procedure initializes the program and opens the
input file}

var
  s: string

begin
  repeat
    write('>')
    readin(s);
  until length(s) = 0;
  writein('Welcome to Syn_Gene_Formatter Version 1.0 -
copyright (c) Glen A. Evans 1997');
  write('Enter the input file name: ');
  readin(infile);
  write('Enter the outputfile name: ');
  readin(outfile);
  write('Enter the length of oligos you wish to use:
');
  readin(oligolength);
  write('Enter the reverse oligo offset value: ');
  readin(offset);
  writein('Thank you. ');
  write('The program will now format the sequence into
oligonucleotide fragments of length ');
  write(oligolength);
  writein;
  writein;

end; {initialize}

procedure readinseq:
var
  j: integer;
  nuc: char;
```

FIG. 7B

17/21

```
begin
  writein('reading input file');
  seqlength:=1;
  while not eof(f) do
    begin
      read(f, nuc);
      if nuc <> '' then
        begin
          if nuc = 'G' then
            dna[seqlength] := nuc;
          if nuc = 'A' then
            dna[seqlength] := nuc;
          if nuc = 'T' then
            dna[seqlength] := nuc;
          if nuc = 'C' then
            dna[seqlength] := nuc;
          if nuc = 'X' then
            dna[seqlength] := nuc;
          if nuc = 'N' then
            dna[seqlength] := nuc;
          seqlength := seqlength + 1;
        end;
      end;

      seqlength := seqlength - 1;

    end; {readinseq}

  procedure readinfile;

  begin
    reset(f, infile);
    readinseq;
    close(f);
```

FIG. 7C

18/21

```
end; {readinfile}
```

```
procedure writeforseq;
```

```
var
```

```
  i, h, b, on: integer;
```

```
begin
```

```
  write ('fragmenting sequence into forward oligos');
```

```
  b:= 1;
```

```
  on:= 1;
```

```
  rewrite(g, outfile);
```

```
  writein(g, infile);
```

```
while b < seqlength + 1 do
```

```
begin
```

```
  write('.');
```

```
  write(g, 'Foligo No.', on, '.');
```

```
begin
```

```
  for h:= 1 to oligolength do
```

```
begin
```

```
  write(g, dna[b]);
```

```
  b:= b + 1;
```

```
end;
```

```
on:= on + 1;
```

```
writein(g);
```

```
end;
```

```
end;
```

```
writein;
```

```
end; {writeforseq}
```

FIG. 7D

19/21

```
procedure reverseseq;
```

```
{This procedure generates the reverse complement of the  
sequence}
```

```
var
```

```
  i, h, b, a, on: integer;
```

```
begin
```

```
write('generating the reverse complement');
```

```
b := seqlength;
```

```
for a := 1 to seqlength do
```

```
  begin
```

```
    if dna[b] = 'G' then
```

```
      rdna[a] := 'C';
```

```
    if dna[b] = 'A' then
```

```
      rdna[a] := 'T';
```

```
    if dna[b] = 'T' then
```

```
      rdna[a] := 'A';
```

```
    if dna[b] = 'C' then
```

```
      rdna[a] := 'G';
```

```
    b := b - 1;
```

```
    write('.');
```

```
  end;
```

```
writeIn;
```

```
end;    {reverseseq}
```

```
procedure writerevseq;
```

FIG. 7E

20/21

{This procedure fragments the reverse complement sequence starting at the offset value}

var

i, h, b, on: integer;

begin

write ('fragmenting sequence into reverse oligos');

on := 1;

b := offset;

while b < sesqlength do

begin

writeIn(g);

write(g, 'Oligo No.', on, ' ');

begin

for h := 1 to oligolength do

begin

write(g, rdna[b]);

b := b + 1;

end;

on := on + 1;

write(' ');

end;

end;

end; {writerevseq}

procedure finaloligo;

var

b, a: integer;

FIG. 7F

21/21

```
begin
  writein;
  writein('generating the last portion of the final
oligo...');
  for a := 1 to offset do
    begin
      write(g, rdna[a])

    end;
  writein(g);
  close(g);

end; {finaloligo}

begin {main}

  initialize;
  readinfile;
  writeforseq;
  reverseseq;
  writerevseq;
  finaloligo;
  writein('processing completed');
  writein('Have a nice day . ');

end. {main}
```

FIG. 7G

SUBSTITUTE SHEET (RULE 26)

SEQUENCE LISTING

<110> Evans, Glen A.

<120> METHOD FOR THE COMPLETE CHEMICAL SYNTHESIS AND ASSEMBLY
OF GENES AND GENOMES

<130> UTFD:572P

<140> Unknown

<141> 1998-09-16

<150> US 60/059,017

<151> 1997-09-16

<160> 193

<170> PatentIn Ver. 2.0

<210> 1

<211> 4800

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
plasmid

<400> 1

```
aagcttacct cgatttgagg acgttacaag tattactggt aaggagcgta gattaaaaaa 60
tgaaattgaa aatgaattat tagaattggc ttaaataaac agaataacca aaaaggaata 120
gagtagaag tttggaaata tttgtttttc gtatcaacca ccagggtgaaa ctcataagct 180
aagtaatgga tcgctttggt cggtttggta tcgcctcaga agagtagggt ttgatacata 240
ttggacctta gaacatcatt ttacagagtt tggctctacg ggaaatttat ttgttgctgc 300
ggctaacctg ttaggaagaa ctaaaacatt aaatgttggc actatggggg ttgttattcc 360
gacagcacac ccagttcgac agttagaaga cgttttatta ttagatcaaa tgtcgaaagg 420
tcgttttaat tttggaaccg ttcgagggct ataccataaa gattttcgag tatttggtgt 480
tgatatgga gagtctcgag caattactca aaatttctac cagatgataa tggaaagctt 540
acagacagga accattagct ctgatagtga ttacattcaa tttcctaagg ttgatgtata 600
tcccaaagtg tactcaaaaa atgtaccaac ctgtatgact gctgagtcg caagtacgac 660
agaatggcta gcaatacaag ggctaccaat ggttcttagt tggattattg gtactaatga 720
aaaaaaagca cagatggaac tctataatga aattgcgaca gaatatgggtc atgatatatc 780
taaaatagat cattgtatga cttatatattg ttctgttgat gatgatgcac aaaaggcgca 840
agatgtttgt cgggagtttc tgaaaaattg gtatgactca tatgtaaatg cgaccaatat 900
ctttaatgat agcaatcaaa ctctgggtta tgattatcat aaagggtcaat ggcgtgattt 960
tgttttacaa ggacatacaa acaccaatcg acgtgttgat tatagcaatg gtattaaccc 1020
tgtaggcact cctgagcagt gtattgaaat cattcaacgt gatattgatg caacgggtat 1080
tacaacatt acatgcggtt ttgaagctaa tggaactgaa gatgaaataa ttgcttccat 1140
gcgacgcttt atgacacaag tcgctccttt cttaaaagaa cctaaataaa ttacttattt 1200
gatactagag ataataagga acaagttatg aaatttggat tattttttct aaactttcag 1260
aaagatggaa taacatctga agaaacgttg gataatatgg taaagactgt cactgtaatt 1320
gattcaacta aatatcattt taatactgcc tttgttaatt aacatcactt ttcaaaaaat 1380
ggattattgt gagcaoctat taccgcagct ggttttttat taggggttaac aaataaatta 1440
catattgggt cattaaatca agtaattacc acccatcacc ctgtacgtgt agcagaagaa 1500
gccagtttat tagatcaaat gtcagaggga cgcttcattc ttgggttttag tgactgcgaa 1560
agtgatttcg aaatggaatt ttttagacgt catatctcat caaggcaaca acaatttgaa 1620
gcatgctatg aaataattaa tgacgcatta actacaggtt attgtcatcc ccaaaacgac 1680
```

ttttatgatt ttccaaaggt ttcaattaat ccacactggt acagtgagaa tggacctaag 1740
caatatgtat ccgctacatc aaaagaagtc gtcattgtggg cagcgaaaaa ggcactgcct 1800
ttaacattta agtgggagga taatttagaa accaaagaac gctatgcaat tctatataat 1860
aaaacagcac aacaatatgg tattgatatt tcggatgttg atcatcaatt aactgtaatt 1920
gcgaacttaa atgctgatag aagtacggct caagaagaag tgagagaata cttaaaagac 1980
tatatcactg aaacttaccc tcaaatggac agagatgaaa aaattaactg cattattgaa 2040
gagaatgcag ttgggtctca tgatgactat tatgaatcga caaaattagc agtggaaaaa 2100
acagggctca aaaatatattt attatccttt gaatacaatgt ccgatattaa agatgtaaaa 2160
gatattattg atatgttgaa ccaaaaaatc gaaatgaatt taccataata aaattaaagg 2220
caatttctat attagattgc ctttttgggg atcctctaga aatattttat ctgattaata 2280
agatgagaat tcaactggcg tcgtttttaca acgtcgtgac tgggaaaacc ctggcggttac 2340
ccaacttaat cgccttgacg cacatcccc tttcgccagc tggcgtaata gcgaagaggc 2400
ccgcacccgat cgccttccc aacagttgcg cagcctgaat ggcgaaatggc gcctgatgcg 2460
gtattttctc cttacgcac tgtgcggtat ttcacaccgc atatggtgca ctctcagtac 2520
aatctgctct gatgccgat agttaagcca gccccgacac ccgccaacac ccgctgacgc 2580
gccctgacgg gcttgtctgc tcccggcatc cgcttacaga caagctgtga ccgtctccgg 2640
gagctgcacg tgcagagggt ttccaccgctc atcaccgaaa cgcgcgagac gaaagggcct 2700
cgtgatacgc ctatttttat aggttaatgt catgataata atggtttctt agacgtcagg 2760
tggcactttt cggggaaatg tgcgcggaac ccctatttgt ttatttttct aaaaagcttc 2820
acgtgcccgc aagcactcag ggcgcaaggg ctgctaaagg aagcggaaca cgtagaaagc 2880
cagtccgcag aaacggtgct gaccccggt gaatgtcagc tactgggcta totggacaag 2940
ggaaaacgca agcgcaaaga gaaagcaggt agcttgacgt gggcttacat ggcgatagct 3000
agactgggcg gttttatgga cagcaagcga accggaattg ccagctgggg cgccctctgg 3060
taagggtggg aagccctgca aagtaaatc gatggcttct ttgccgccaa ggatctgatg 3120
gcgcagggga tcaagatctg atcaagagac aggatgagga tcgtttcgca tgattgaaca 3180
agatgggatt cagcaggtt ctccggccgc ttgggtggag aggctattcg gctatgactg 3240
ggcacaacag acaatcggct gctctgatgc cgccgtgttc cggctgtcag cgcaggggcg 3300
cccgttctt tttgtcaaga ccgacctgtc cgctgcccctg aatgaactgc aggacgaggc 3360
agcgcggcta tcgtggctgg ccacgacggg cggttccctgc gcagctgtgc toacgttgt 3420
cactgaagcg ggaagggact ggctgctatt gggcgaaagt ccggggcagg atctcctgtc 3480
atctcacctt gctcctgcc agaaagtatc catcatggct gatgcaatgc ggcggctgca 3540
tacgcttgat ccggctacct gccattcga ccaccaagcg aaacatcgca tcgagcgagc 3600
acgtactcgg atggaagccg gtcttgcga tcaggatgat ctggacgaag agcatcaggg 3660
gctcgcgcca gccgaactgt tcgccaggct caaggcgcg atgcccgac gcgaggatct 3720
cgctcgtgac catggcgatg cctgcttgcc gaatatcatg gtggaaaatg gccgcttttc 3780
tggattcatc gactgtggcc ggctgggtgt ggcggaccgc tatcaggaca tagcgttggc 3840
taccctgat attgctgaag agcttggcgg cgaatgggct gaccgcttcc tcgtgcttta 3900
cggatcgcg gctcccgatt cgcagcgcat cgcttctat cgccttcttg acgagttctt 3960
ctgagcggga ctctggggtt cgaaatgacc gaccaagcga cgcccaacct gccatcacga 4020
gatttcgatt ccaccgcgc cttctatgaa aggttgggct tcggaatcgt ttccggggac 4080
gccggctgga tgatcctcca gcgcggggat ctcatgctgg agttcttcgc ccacccggg 4140
catgacaaaa atcccttaac gtgagttttc gttccactga gcgtcagacc ccgtagaaaa 4200
gatcaaagga tcttcttgag atcctttttt tctgcgcgta atctgctgct tgcaaacaaa 4260
aaaaccaccg ctaccagcgg tggtttgttt gccggatcaa gagctaccaa ctctttttcc 4320
gaaggtaact ggcttcagca gagcgcagat accaaatact gtccttctag tgtagccgta 4380
gttaggccac cacttcaaga actctgtagc accgcctaca tacctcgctc tgctaatacct 4440
gttaccagt gctgctgcca gtggcgataa gtcgtgtctt accgggttgg actcaagacg 4500
atagttaccg gataaggcgc agcggtcggg ctgaacgggg ggttcgtgca cacagcccag 4560
cttgagcgca acgacctaca ccgaactgag atacctacag cgtgagctat gagaaagcgc 4620
cacgcttccc gaagggagaa aggcggacag gtatccggta agcggcaggg tcggaacagg 4680
agagcgcacg agggagcttc cagggggaaa cgcctggtat ctttatagtc ctgtcgggtt 4740
tcgccacctc tgacttgagc gtcgattttt gtgatgctcg tcaggggggc ggagcctatg 4800

<210> 2

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 2

aagcttacct cgatttgagg acgttacaag tattactggt aaggagcgta 50

<210> 3

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 3

gattaaaaaa tgaaattgaa aatgaattat tagaattggc ttaaataaac 50

<210> 4

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 4

agaatcacca aaaaggaata gagtatgaag ttgggaaata ttgttttttc 50

<210> 5

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 5

gtatcaacca ccaggtgaaa ctcataagct aagtaatgga tcgctttggt 50

<210> 6

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 6

cggcttggtgta tcgcctcaga agagtaggggt ttgatacata ttggacctta 50

<210> 7

<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 7
gaacatcatt ttacagagtt tggctttacg ggaaatttat ttgttgctgc 50

<210> 8
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 8
ggctaacctg ttaggaagaa ctaaacatt aaatgttggc actatggggg 50

<210> 9
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 9
ttgttattcc gacagcacac ccagttcgac agttagaaga cgttttatta 50

<210> 10
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 10
ttagatcaaa tgtcgaaagg tcgttttaaat ttggaaccg ttcgagggt 50

<210> 11
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 11

ataccataaa gattttcgag tatttggtgt tgatatggaa gagtctcgag 50

<210> 12

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 12

caattactca aaatttctac cagatgataa tggaaagctt acagacagga 50

<210> 13

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 13

accattagct ctgatagtga ttacattcaa tttcctaagg ttgatgtata 50

<210> 14

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 14

tcccaaagtg tactcaaaaa atgtaccaac ctgtatgact gctgagtcg 50

<210> 15

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 15

caagtacgac agaattggcta gcaatacaag ggctaccaat ggttcttagt 50

<210> 16

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

Oligonucleotide

<400> 16
tggattattg gtactaatga aaaaaagca cagatggaac tctataatga 50

<210> 17
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 17
aattgcgaca gaatatggtc atgatataac taaaatagat cattgtatga 50

<210> 18
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 18
cttatatttg ttctgttgat gatgatgcac aaaaggcgca agatgtttgt 50

<210> 19
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 19
cgggagtttc tgaaaaattg gtatgactca tatgtaaatg cgaccaatat 50

<210> 20
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 20
ctttaatgat agcaatcaaa ctctgtggtta tgattatcat aaaggtcaat 50

<210> 21
<211> 50
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 21

ggcgtgattt tgttttacaa ggacatacaa acaccaatcg acgtgttgat 50

<210> 22

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 22

tatagcaatg gtattaaccc tgtaggcact cctgagcagt gtattgaaat 50

<210> 23

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 23

cattcaacgt gatattgatg caacgggtat tacaacatt acatgcggat 50

<210> 24

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 24

ttgaagctaa tggaactgaa gatgaaataa ttgcttccat gcgacgcttt 50

<210> 25

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 25

atgacacaag tcgctccttt cttaaaagaa cctaaataaa ttacttattt 50

<210> 26

<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 26
gatactagag ataataagga acaagttatg aaatttggat tattttttct 50

<210> 27
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 27
aaactttcag aaagatggaa taacatctga agaaacgttg gataatatgg 50

<210> 28
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 28
taaagactgt cacgttaatt gattcaacta aatatcattt taatactgcc 50

<210> 29
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 29
tttgttaatg aacatcactt ttcaaaaaat ggtattgttg gagcacctat 50

<210> 30
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 30

taccgcagct gggttttttat taggggtaac aaataaatta catattggtt 50

<210> 31

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 31

cattaaatca agtaattacc acccatcacc ctgtacgtgt agcagaagaa 50

<210> 32

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 32

gccagtttat tagatcaaat gtcagaggga cgcttcattc ttggtttttag 50

<210> 33

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 33

tgactgcgaa agtgatttcg aaatggaatt ttttagacgt catatctcat 50

<210> 34

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 34

caaggcaaca acaatttgaa gcatgctatg aaataattaa tgacgcatta 50

<210> 35

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

Oligonucleotide

<400> 35
actacaggtt attgtcatcc ccaaaacgac ttttatgatt ttccaaaggt 50

<210> 36
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 36
ttcaattaat ccacactggt acagtgagaa tggacctaag caatatgtat 50

<210> 37
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 37
ccgctacatc aaaagaagtc gtcattgtggg cagcgaaaaa ggcactgcct 50

<210> 38
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 38
ttaacattta agtggggagga taatttagaa accaaagaac gctatgcaat 50

<210> 39
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 39
tctatataat aaaacagcac aacaatatgg tattgatatt tcggatgttg 50

<210> 40
<211> 50
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 40

atcatcaatt aactgtaatt gcgaacttaa atgctgatag aagtacggt 50

<210> 41

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 41

caagaagaag tgagagaata cttaaaagac tatatcactg aaacttaccc 50

<210> 42

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 42

tcaaatggac agagatgaaa aaattaactg cattattgaa gagaatgcag 50

<210> 43

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 43

ttgggtctca tgatgactat tatgaatcga caaaattagc agtggaaaaa 50

<210> 44

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 44

acagggtcta aaaatatttt attatccttt gaatcaatgt ccgatattaa 50

<210> 45

<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 45
agatgtaaaa gatattattg atatgttgaa ccaaaaaatc gaaatgaatt 50

<210> 46
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 46
taccataata aaattaaagg caatttctat attagattgc ctttttgggg 50

<210> 47
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 47
atcctctaga aatattttat ctgattaata agatgagaat tcaactggccg 50

<210> 48
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 48
tcgtttttaca acgtcgtgac tgggaaaacc ctggcggttac ccaacttaat 50

<210> 49
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 49

cgcccttgag cacatcccc ttcgccagc tggcgtaata gcgaagaggc 50

<210> 50

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 50

ccgcaccgat cgcccttccc aacagttgcg cagcctgaat ggcgaatggc 50

<210> 51

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 51

gcctgatgag gtattttctc cttacgcac tgtgcggtat ttcacaccgc 50

<210> 52

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 52

atatggtgca ctctcagtac aatctgctct gatgccgcat agttaagcca 50

<210> 53

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 53

gccccgacac ccgccaacac ccgctgacgc gccctgacgg gcttgctgcg 50

<210> 54

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

Oligonucleotide

<400> 54
tcccggcatc cgcttacaga caagctgtga ccgtctccgg gagctgcatg 50

<210> 55
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 55
tgtcagaggt tttcacgctc atcaccgaaa cgcgcgagac gaaagggcct 50

<210> 56
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 56
cgtgatacgc ctatttttat aggttaatgt catgataata atggtttctt 50

<210> 57
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 57
agacgtcagg tggcactttt cggggaaatg tgcgcggaac ccctatttgt 50

<210> 58
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 58
ttatttttct aaaaagcttc acgctgccgc aagcactcag ggcgcaaggg 50

<210> 59
<211> 50
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 59

ctgctaaagg aagcggaaca cgtagaaagc cagtcgcgag aaacgggtgct 50

<210> 60

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 60

gaccccgat gaatgtcagc tactgggcta tctggacaag ggaaaacgca 50

<210> 61

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 61

agcgcaaaga gaaagcaggt agcttgcagt gggcttacat ggcgatagct 50

<210> 62

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 62

agactgggcg gttttatgga cagcaagcga accggaattg ccagctgggg 50

<210> 63

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 63

cgccctctgg taagggtggg aagccctgca aagtaaactg gatggctttc 50

<210> 64

<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 64
ttgccgcctaa ggatctgatg gcgcagggga tcaagatctg atcaagagac 50

<210> 65
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 65
aggatgagga tcgtttcgca tgattgaaca agatggattg cacgcaggtt 50

<210> 66
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 66
ctccggccgc ttgggtggag aggctattcg gctatgactg ggcacaacag 50

<210> 67
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 67
acaatcggct gctctgatgc cgccgtgttc eggctgtcag cgcaggggag 50

<210> 68
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 68

cccggttctt tttgtcaaga ccgacctgtc cggcgccctg aatgaactgc 50

<210> 69

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 69

aggacgaggg agcgcggcta tcgtggctgg ccacgacggg cgcttccttg 50

<210> 70

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 70

gcagctgtgc tcgacgttgt cactgaagcg ggaagggact ggctgctatt 50

<210> 71

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 71

gggcgaagtg ccggggcagg atctcctgtc atctcacctt gctcctgccg 50

<210> 72

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 72

agaaagtatc catcatggct gatgcaatgc ggcggtgca tacgcttgat 50

<210> 73

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

Oligonucleotide

<400> 73
ccggctacct gccattcga ccaccaagcg aaacatcgca tcgagcgagc 50

<210> 74
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 74
acgtactcgg atggaagcgg gtcttgctga tcaggatgat ctggacgaag 50

<210> 75
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 75
agcatcaggg gctcgcgcca gccgaactgt tcgccaggct caaggcgcg 50

<210> 76
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 76
atgcccagcg gcgaggatct cgtcgtgacc catggcgatg cctgcttgcc 50

<210> 77
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 77
gaatatcatg gtggaaaatg gccgcttttc tggattcatc gactgtggcc 50

<210> 78
<211> 50
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 78

ggctgggtgt ggcggaccgc tatcaggaca tagcgttggc taaccgtgat 50

<210> 79

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 79

attgctgaag agcttggcgg cgaatgggct gaccgcttcc tcgtgcttta 50

<210> 80

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 80

cggatcgcg gctcccgatt cgcagcgcac cgccttctat cgccttcttg 50

<210> 81

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 81

acgagttctt ctgagcggga ctctgggggt cgaaatgacc gaccaagcga 50

<210> 82

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 82

cgcaccaact gccatcacga gatttcgatt ccaccgccgc cttctatgaa 50

<210> 83

<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 83
agggttgggct tcggaatcgt tttccgggac gccggctgga tgatcctcca 50

<210> 84
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 84
gcgcggggat ctcagtctgg agttcttcgc ccacccggg catgaccaa 50

<210> 85
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 85
atcccttaac gtgagttttc gttccactga gcgtcagacc ccgtagaaaa 50

<210> 86
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 86
gatcaaagga tcttcttgag atcctttttt tctgcgcgta atctgctgct 50

<210> 87
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 87

tgcaaacaaa aaaaccaccg ctaccagcgg tggtttgttt gccggatcaa 50

<210> 88

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 88

gagctaccaa ctctttttcc gaaggtaact ggcttcagca gagcgcagat 50

<210> 89

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 89

accaaatact gtccttctag tgtagccgta gttaggccac cacttcaaga 50

<210> 90

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 90

actctgtagc accgcctaca tacctcgctc tgctaactct gttaccagtg 50

<210> 91

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 91

gctgctgcc a gtggcgataa gtcgtgtctt accgggttgg actcaagacg 50

<210> 92

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

Oligonucleotide

<400> 92
atagttaccg gataaggcgc agcggtcggg ctgaacgggg ggttcgtgca 50

<210> 93
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 93
cacagcccag cttggagcga acgacctaca ccgaactgag atacctacag 50

<210> 94
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 94
cgtgagctat gagaaagcgc cacgcttccc gaaggggagaa aggcgacag 50

<210> 95
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 95
gtatccggtg agcggcaggg tcggaacagg agagcgcacg agggagcttc 50

<210> 96
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 96
cagggggaaa cgcctggtat ctttatagtc ctgtcgggtt tcgccacctc 50

<210> 97
<211> 50
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 97

tgacttgagc gtcgattttt gtgatgctcg tcaggggggc ggagcctatg 50

<210> 98

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 98

catcacaaaa atcgacgctc aagtcagagg tggcgaaacc cgacaggact 50

<210> 99

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 99

ataaagatac caggcgtttc cccctggaag ctccctcgtg cgctctcctg 50

<210> 100

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 100

ttccgaccct gccgcttacc ggatacctgt ccgcctttct cccttcggga 50

<210> 101

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 101

agcgtggcgc ttttcatag ctcacgctgt aggtatctca gttcggtgta 50

<210> 102

<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 102
ggtcgttcgc tccaagctgg gctgtgtgca cgaaccccc gttcagcccg 50

<210> 103
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 103
accgctgcgc cttatccggt aactatcgtc ttgagtccaa cccggtgaaga 50

<210> 104
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 104
cacgacttat cgccactggc agcagccact ggtaacagga ttagcagagc 50

<210> 105
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 105
gaggtatgta ggcggtgcta cagagttctt gaagtgggtg cctaactacg 50

<210> 106
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 106

gctacactag aaggacagta ttggtatct gcgctctgct gaagccagtt 50

<210> 107

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 107

accttcggaa aaagagttgg tagctcttga tccggcaaac aaaccaccgc 50

<210> 108

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 108

tggtagcggg ggtttttttt ttgcaagca gcagattacg cgcagaaaaa 50

<210> 109

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 109

aaggatctca agaagatcct ttgatctttt ctacgggggc tgacgctcag 50

<210> 110

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 110

tggaacgaaa actcacgtta agggattttg gtcatgcccg gggtagggcga 50

<210> 111

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

Oligonucleotide

<400> 111
agaactccag catgagatcc ccgcgctgga ggatcatcca gccggcgtcc 50

<210> 112
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 112
cggaaaacga ttccgaagcc caacctttca tagaaggcgg cgggtggaatc 50

<210> 113
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 113
gaaatctcgt gatggcaggt tgggcgtcgc ttggtcggtc atttcgaacc 50

<210> 114
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 114
ccagagtccc gctcagaaga actcgtcaag aaggcgatag aaggcgatgc 50

<210> 115
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 115
gctgcgaatc gggagcggcg ataccgtaaa gcacgaggaa gcggtcagcc 50

<210> 116
<211> 50
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 116

cattcgccgc caagctcttc agcaatatca cgggtagcca acgctatgtc 50

<210> 117

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 117

ctgatagcgg tccgccacac ccagccggcc acagtogatg aatccagaaa 50

<210> 118

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 118

agcggccatt ttccaccatg atattcggca agcaggcatc gccatgggtc 50

<210> 119

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 119

acgacgagat cctcgccgtc gggcatgcgc gcottgagcc tggcgaacag 50

<210> 120

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 120

ttcggctggc gcgagcccct gatgctcttc gtccagatca tcctgatoga 50

<210> 121

<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 121
caagaccggc ttccatccga gtacgtgctc gctcgatgcg atgtttcgct 50

<210> 122
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 122
tggtggcgca atgggcaggc agccggatca agcgtatgca gccgccgcat 50

<210> 123
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 123
tgcatcagcc atgatggata ctttctcggc aggagcaagg tgagatgaca 50

<210> 124
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 124
ggagatcctg ccccggcact tcgccaata gcagccagtc ccttcccgt 50

<210> 125
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 125

tcagtgcacaa cgtcgagcac agctgcgcaa ggaacgcccg tcgtggccag 50

<210> 126

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 126

ccacgatagc cgcgctgcct cgtcctgcag ttcattcagg gcaccggaca 50

<210> 127

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 127

ggtcggctctt gacaaaaaga accgggagcc cctgcgctga cagccggaac 50

<210> 128

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 128

acggcgcat cagagcagcc gattgtctgt tgtgcccagt catagccgaa 50

<210> 129

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 129

tagcctctcc acccaagcgg ccggagaacc tgcgtgcaat ccatcttgtt 50

<210> 130

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

Oligonucleotide

<400> 130
caatcatgcg aaacgatacct catcctgtct cttgatcaga tcttgatccc 50

<210> 131
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 131
ctgcgccatc agatccttgg cggcaagaaa gccatccagt ttactttgca 50

<210> 132
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 132
gggcttccca accttaccag agggcgcccc agctggcaat tccggttcgc 50

<210> 133
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 133
ttgctgtcca taaaaccgcc cagtctagct atcgccatgt aagcccactg 50

<210> 134
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 134
caagctacct gctttctctt tgcgcttgcg ttttcccttg tccagatagc 50

<210> 135
<211> 50
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 135

ccagtagctg acattcatcc ggggtcagca ccgtttctgc ggactggctt 50

<210> 136

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 136

tctacgtgtt ccgcttcctt tagcagccct tgcgccctga gtgcttgagg 50

<210> 137

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 137

cagcgtgaag ctttttagaa aaataaaca ataggggttc cgcgacatt 50

<210> 138

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 138

tccccgaaaa gtgccacctg acgtctaaga aaccattatt atcatgacat 50

<210> 139

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 139

taacctataa aaataggcgt atcacgaggc cctttcgtct cgcgcgtttc 50

<210> 140

<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 140
ggtgatgacg gtgaaaacct ctgacacatg cagctcccgg agacggtcac 50

<210> 141
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 141
agcttgtctg taagcggatg ccgggagcag acaagcccg t cagggcgcg t 50

<210> 142
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 142
cagcgggtgt tggcgggtgt cggggctggc ttaactatgc ggcacagag 50

<210> 143
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 143
cagattgtac tgagagtgc ccatatgcgg tgtgaaatac cgcacagatg 50

<210> 144
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 144

cgtaaggaga aaataccgca tcaggcgcca ttcgccattc aggtgcgca 50

<210> 145
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 145
actgttggga agggcgatcg gtgcgggcct ctctgctatt acgccagctg 50

<210> 146
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 146
gcgaaagggg gatgtgctgc aaggcgatta agttgggtaa cgccagggtt 50

<210> 147
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 147
ttcccagtca cgacgttgta aaacgacggc cagtgaattc tcattttatt 50

<210> 148
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 148
aatcagataa aatattttcta gaggatcccc aaaaaggcaa tctaatatag 50

<210> 149
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

Oligonucleotide

<400> 149
aaattgcctt taattttatt atggtaaatt catttcgatt ttttggttca 50

<210> 150
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 150
acatatcaat aatatctttt acatctttaa tatcgacat tgattcaaag 50

<210> 151
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 151
gataataaaa tatttttaga cctgtttt tccactgcta atttgtcga 50

<210> 152
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 152
ttcataatag tcatcatgag acccaactgc attctcttca ataatgcagt 50

<210> 153
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 153
taattttttc atctctgtcc atttgagggt aagtttcagt gatatagtct 50

<210> 154
<211> 50
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 154

tttaagtatt ctctcacttc ttcttgagcc gtactttctat cagcatttaa 50

<210> 155

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 155

gttcgcaatt acagttaatt gatgatcaac atccgaaata tcaataccat 50

<210> 156

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 156

attgttgtgc tgttttatta tatagaattg catagcgttc ttgggtttct 50

<210> 157

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 157

aaattatcct ccacttaaa tgtaaaggc agtgcctttt tcgctgccca 50

<210> 158

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 158

catgacgact tcttttgatg tagcggatac atattgctta ggtccattct 50

<210> 159

<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 159
cactgtaaca gtgtggatta attgaaacct ttggaaaatc ataaaagtcg 50

<210> 160
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 160
ttttggggat gacaataacc ttagttaat gcgtcattaa ttatttcata 50

<210> 161
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 161
gcatgcttca aattgttggt gccttgatga gatatgacgt ctaaaaaatt 50

<210> 162
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 162
ccatttcgaa atcactttcg cagtcactaa aaccaagaat gaagcgtccc 50

<210> 163
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 163

tctgacattt gatctaataa actggcttct tctgctacac gtacaggggtg 50

<210> 164

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 164

atgggtggta attacttgat ttaatgaacc aatatgtaat ttatttgta 50

<210> 165

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 165

accctaataa aaaaccagct gcggaatag gtgctccaac aataccattt 50

<210> 166

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 166

tttgaaaagt gatgttcatt aacaaaggca gtattaaaat gatatttagt 50

<210> 167

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 167

tgaatcaatt aacgtgacag tctttaccat attatccaac gtttcttcag 50

<210> 168

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

Oligonucleotide

<400> 168
atgttattcc atctttctga aagtttagaa aaaataatcc aaatttcata 50

<210> 169
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 169
acttggtcct tattatctct agtatcaaag aagtaattta tttaggttct 50

<210> 170
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 170
tttaagaaag gagcgacttg tgcataaag cgtcgcatgg aagcaattat 50

<210> 171
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 171
ttcatcttca gttccattag cttcaaatacc gcatgtaatg ttgtaatac 50

<210> 172
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 172
ccgttgcatc aatatcacgt tgaatgattt caatacactg ctcaggagtg 50

<210> 173
<211> 50
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 173

cctacagggt taataccatt gctataatca acacgtcgat tgggtgttgt 50

<210> 174

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 174

atgtccttgt aaaacaaaat cacgccattg acctttatga taatcataac 50

<210> 175

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 175

cacgagtttg attgctatca ttaaagatat tggtcgcatt tacatatgag 50

<210> 176

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 176

tcataccaat ttttcagaaa ctcccagaaa acatcttgcg ccttttgtgc 50

<210> 177

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 177

atcatcatca acagaacaaa tataagtcac acaatgatct attttagata 50

<210> 178

<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 178
tatcatgacc atattctgtc gcaatttcat tatagagttc catctgtgct 50

<210> 179
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 179
tttttttcat tagtaccaat aatccaacta agaaccattg gtagcccttg 50

<210> 180
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 180
tattgctagc cattctgtcg tacttgcgga ctcagcagtc atacaggttg 50

<210> 181
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 181
gtacattttt tgagtacact ttgggatata catcaacctt aggaaattga 50

<210> 182
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 182

atgtaatcac tatcagagct aatgggtcct gtctgtaagc tttccattat 50

<210> 183

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 183

catctggttag aaattttgag taattgctcg agactcttcc atatcaacac 50

<210> 184

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 184

caaatactcg aaaatcttta tggtatagcc ctggaacggt tccaaaatta 50

<210> 185

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 185

aaacgacctt tcgacatttg atctaataat aaaacgtctt ctaactgtcg 50

<210> 186

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 186

aactgggtgt gctgtcggaa taacaacccc catagtgcc aattttaatg 50

<210> 187

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

Oligonucleotide

<400> 187
tttttagttct tcctaacagg ttagccgcag caacaaataa atttcccgtg 50

<210> 188
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 188
agaccaaact ctgtaaaatg atgttctaag gtccaatatg tatcaaaccg 50

<210> 189
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 189
tactcttctg aggcgatacc aagccgaaca aagcgatcca ttacttagct 50

<210> 190
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 190
tatgagtttc acctggtggt tgatacgaaa aacaaatatt tccaaacttc 50

<210> 191
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 191
atactctatt cctttttggt gattctgttt atttaagcca attctaataa 50

<210> 192
<211> 50
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 192

ttcattttca atttcatttt ttaatctacg ctccttaaca gtaatacttg 50

<210> 193

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 193

taacgtcctc aaatcgaggt aagcttcata ggctccgcc cctgaagag 50

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/19312

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/10 C12Q1/68 C07H21/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C12Q C07H

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WOSNICK M A ET AL: "TOTAL CHEMICAL SYNTHESIS AND EXPRESSION IN ESCHERICHIA COLI OF A MAIZE GLUTATHIONE-TRANSFERASE (GST) GENE" GENE, vol. 76, 1984, pages 153-160, XP002026707 see the whole document	1-41
X	L.D. BELL ET AL.: "Chemical synthesis, cloning and expression in mammalian cells of a gene coding for human tissue-type plasminogen activator" GENE, vol. 63, 1988, pages 155-163, XP002089326 ELSEVIER SCIENCE PUBLISHERS, B.V., AMSTERDAM, NL: see the whole document	1-41



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

7 January 1999

Date of mailing of the international search report

15/02/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Hornig, H

INTERNATIONAL SEARCH REPORT

Int. Application No

PCT/US 98/19312

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	M.D. EDGE ET AL.: "Total synthesis of a human leukocyte interferone gene" NATURE, vol. 292, 20 August 1981, pages 756-762, XP002089327 MACMILLAN JOURNALS LTD., LONDON, UK see the whole document ---	1-41
X	L. FERRETTI ET AL.: "Total synthesis of a gene for bovine rhodopsin" PROC. NATL. ACAD. SCI., vol. 83, February 1996, pages 599-603, XP002089328 NATL. ACAD. SCI., WASHINGTON, DC, US; see the whole document ---	1-41
X	EP 0 385 410 A (CANON KK) 5 September 1990 see the whole document ---	1-41
X	EP 0 316 018 A (CETUS CORP) 17 May 1989 see the whole document ---	1-41
X	WO 94 12632 A (UNIV LONDON ; PRODRIMOU CHRISOSTOMOS (GB); PEARL LAURENCE HARRIS (G) 9 June 1994 see the whole document ---	1-41
X	WO 90 00626 A (BAYLOR COLLEGE MEDICINE) 25 January 1990 see the whole document ---	1-41
A	LASHKARI D A ET AL: "AN AUTOMATED MULTIPLEX OLIGONUCLEOTIDE SYNTHESIZER: DEVELOPMENT OF HIGH-THROUGHPUT, LOW-COST. DNA SYNTHESIS" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 92, no. 17, 15 August 1995, pages 7912-7915, XP000611248 see the whole document ---	1-41
A	L.E. SINDELAR AND J.M. JAKLEVIC: "High-throughput DNA synthesis in a multichannel format" NUCLEIC ACIDS RESEARCH, vol. 23, no. 6, 1995, pages 982-987, XP002089329 IRL PRESS LIMITED, OXFORD, ENGLAND see the whole document ---	1-41
	--- -/--	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/19312

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No. 1
P, A	<p>S. RAYNER ET AL.: "MerMade: An oligodeoxyribonucleotide synthesizer for high throughput oligonucleotide production in dual 96-well plates"</p> <p>GENOME RESEARCH, vol. 8, no. 7, July 1998, pages 741-747, XP002089330</p> <p>CSH LABORATORY PRESS</p> <p>cited in the application</p> <p>see the whole document</p> <p>-----</p>	1-41

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/19312

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0385410 A	05-09-1990	JP 3210195 A	13-09-1991
		JP 3232489 A	16-10-1991
		JP 3232490 A	16-10-1991
		JP 3127999 A	31-05-1991
		JP 3007583 A	14-01-1991
		AT 143696 T	15-10-1996
		DE 69028725 D	07-11-1996
		DE 69028725 T	13-03-1997
		US 5830643 A	03-11-1991
EP 0316018 A	17-05-1989	EP 0196762 A	08-10-1986
		EP 0314202 A	03-05-1989
		JP 2579619 B	05-02-1997
		JP 61293916 A	24-12-1986
		JP 2574142 B	22-01-1997
		JP 8048700 A	20-02-1996
		US 5079163 A	07-01-1992
		US 5538868 A	23-07-1996
WO 9412632 A	09-06-1994	NONE	
WO 9000626 A	25-01-1990	AU 3869289 A	05-02-1990
		EP 0427745 A	22-05-1991
		JP 3505966 T	26-12-1991

